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Abstract 
 
Influenza A virus (IAV) causes significant mortality, morbidity, and financial burden throughout 
the world. IAV is a negative, single-stranded, and segmented RNA virus of the 
Orthomyxoviridae family. IAV subtypes are determined based on its two surface glycoproteins, 
hemagglutinin (HA) and neuraminidase (NA). H1N1 and H3N2 are the major circulating 
subtypes among humans. Frequent genotyping of IAV strains throughout the influenza season is 
crucial for the identification of circulating subtypes and subsequently the choice of the H3N2 and 
H1N1 subtypes’ lineages to be included in the annually prepared vaccine cocktail.  Sequencing 
and identification of circulating subtypes in the region continues to be less frequent and less 
intensive than in other parts of the world, despite increasing interest and efforts made ever since 
the swine H1N1 outbreak in 2009.   This work presents the first comprehensive study on IAV 
circulating in Palestine.  200 Nasopharyngeal aspirate (NPA) samples were collected between 
February 10th and May 5th, 2015 from participants suffering from mild to severe symptoms of 
upper respiratory infections and were screened for the presence of IAV using RT-PCR assays 
amplifying the HA and NA gene regions.  50 samples (25%) tested positive for IAV, 24 (48%) 
were identified as H1N1, and 26 (52%) were identified as H3N2 subtype, respectively.  Infection 
with H1N1 occurred mainly in April, while H3N2 infections were mainly detected in March.  
Most IAV infections in children younger than 6-year-old were attributed to subtypes H3N2, 
while H1N1 was responsible for most infections in adults older than eighteen-year-old.  
Hundred-fifteen sequences of the HA and NA genes were successfully analyzed. These 
sequences belong to 23 IAV positive Palestinian IAV samples.  The percent identity of the 
sequences among Palestinian isolates was higher than that between Palestinian isolates and 
GenBank-archived reference sequences.  14, 15, 22 and 6 non-synonymous substitutions were 
detected in the Palestinian H1, N1, H3 and N2 genes, including novel ones, respectively.  Some 
of these amino acid substitutions localized to the antigenic sites, T202S and Q180K in H1 gene, 
T144A and L173S in H3 gene.  Such substitutions in the antigenic sites may affect the host-
immune response.  Other substitutions located at the receptor binding sites, such as T228A in H3 
gene, may affect viral binding activity to host cell receptor, and subsequently its virulence and 
host species barrier. 
III 
  
 
None of the substitutions detected in this work were associated with drug resistance or fatal 
outcomes.  Phylogenetic analysis revealed that Palestinian H1N1 and H3N2 were not closely 
related to those regionally circulating strains and clustered closer to international, rather non-
regional strains.  The results of this study are significant in providing the first insight into the 
genetic properties of the HA and NA genes of the influenza A viruses circulating in Palestine.  
Finally, this study provides evidence of the efficacy of the seasonal influenza vaccine 2014-2015 
in Palestine. 
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Introduction 
1.1 Historical Background 
Influenza, the flu, belongs to the most common illnesses among humans and is one of the 
diseases described in the ancient history of medicine. The father of medicine, Hippocrates, had 
described an epidemic in 412 BC, which is believed to be influenza (Harris et al., 1919). 
Epidemics with flu-like symptoms including cough, weakness, headaches and flu-like routes of 
transmission were described since early centuries (Harris et al. 1919). The first recognized 
influenza pandemic was in 1510, thereafter, another nine epidemics were identified until the 
well-known “Spanish” influenza pandemic of 1918/1919 (Morens et al., 2010a, Morens et al., 
2010b). 
Centanni and Savunzzi isolated the virus causing “poultry pest”, referred to “fowl plaque virus” 
(FPV), in 1901.  Unknowingly, they marked the first actual isolation of influenza A virus, but it 
was not until 1955, when Schäfer classified FPV as influenza A virus (reviewed in Lupiani and 
Reddy, 2009).  Smith, Andrewes, and Laidlaw isolated the first human influenza A in 1933 
(Wright et al., 2007).  
The “Spanish” influenza pandemic of 1918/1919 caused around 50 million deaths worldwide 
and infected around 500 million people, which was one third of the world’s population 
(Taubenberger and Morens, 2006). It was not until 1997, when modern techniques of molecular 
biology, sequencing and bioinformatics made the identification of the causative influenza virus 
of the pandemic possible (Taubenberger et al., 1997, Reid et al., 1999, Basler et al., 2001). 
Today such techniques are used on daily basis to monitor the circulating influenza viruses, 
contributing efficiently to the yearly selection of the strains/lineages included in the vaccine. 
 
 
1.2  Orthomyxoviridae Family 
Influenza viruses belong to the Orthomyxoviridae virus family. Orthomyxoviridae are viruses 
that have a negative-sense, single-stranded, and segmented RNA genome (Palese and Shaw, 
2007). Negative single stranded RNA is complementary to mRNA (Baltimor, 1971). There are 
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three Influenza viruses genera; A, B and, C, classified in the Orthomyxoviridae family, along 
with another two genera; Thogotovirus and Isavirus (Kawaoka et al., 2005). Recent studies have 
reported the identification of a sixth genus within the Orthomyxoviridae, referred to as influenza 
D virus (Hause et al., 2014, Ducatez et al., 2015). Influenza D virus isolates were previously 
classified within the influenza C viruses, however deep sequencing, phylogenetic analysis and in 
vitro reassortment experiments demonstrated that they are genetically distinct from influenza C 
viruses with around 50% overall homology (Hause et al., 2014, Ducatez et al., 2015). 
 
 
1.3   Nomenclature 
Nomenclature for of Influenza virus strains is very strict and compromises the genus (A, B, or 
C), the host origin (exception human), geographic location of first isolation, the strain number, 
and the year of isolation (WHO, 1980). In case of influenza A isolates, subtype of the viral 
proteins hemagglutinin (HA), referred to as H, and neuraminidase (NA), referred to as N, is 
added in parentheses. For example, a Palestinian human influenza A H1N1 isolate number 01 of 
the year 2013; A/Palestine/01/2013(H1N1), GenBank: KC589437.1, a Hong Kong influenza A 
H5N1 isolate number 822.1 of the year 2001 isolated from chicken; A/Chicken/Hong 
Kong/822.1/01 (H5N1), GenBank: AF509180.2, an influenza B isolate from a seal in 
Netherlands of the year 1999; B/Seal/Netherlands/1/99, GenBank: AF217214.1, and an influenza 
C virus isolate from Japanese Yamagata of the year 1986; C/Yamagata/1/86, GenBank: 
AB000611.1.  
 
 
1.4  Influenza A Virion Structure and Morphology 
The influenza A virus (IAV) is an enveloped virus. The virion is pleiomorphic of 100 nm in 
diameter. Interestingly, in vitro infections produce rather spherical virions, while in vivo 
infections produce filamentous particles, which can have a length over 20 μm (Chu et al., 1949; 
Kilbourne and Murphy, 1960, Nakajima et al., 2010).  
The envelope is the outer membrane, which is a lipid layer derived from the host cell.  Two 
major envelope glycoproteins, hemagglutinin (HA or H), the neuraminidase (NA or N), and the 
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less abundant integral matrix protein M2 are embedded into the envelope and the underlying 
matrix protein M1 (Figure. 1.1). HA and NA are 10-14 nm long and are also known as spikes as 
they can be distinguished in electron micrographs of virion particle. The M2 protein forms ion 
channels in the virion particle.  
 
 
Figure 1.1: Structure of influenza A virion and organization of its genome. The illustration 
of the influenza A virus shows the spikes of HA and NA glycoproteins embedded through the 
envelope all the way to the matrix 1 (M1) protein, while matrix 2 (M2) forms an ion channel and 
is embedded in the core of the virion. The core of the virion contains the eight viral RNA 
segments, each bound to the polymerase complex, coated by NP forming ribonucleoproteins 
(RNPs). The RNPs in the illustration are arranged according to the length of the viral genes (see 
1.4 below), PB2, PB1, PA, HA, NP, NA, M1/M2, NS1/NS2. The illustration was kindly 
provided by Dr. Maysa Azzeh (Azzeh et al., 2000). 
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Matrix protein M1 is the most abundant protein in the virion and surrounds the core of the virion. 
The core of the virion is composed of the eight ribonucleoproteins (RNP). RNP is a complex 
compromised of the viral RNA (vRNA), the viral polymerase protein complex, and the 
nucleoprotein (NP) (Figure 1.1). In fact, the polymerase complex binds the 3’ and 5’ ends of 
each vRNA, while the NP molecules coat the rest of it (Compans et al., 1972, Hsu et al., 1987, 
Fodor et al., 1993). Polymerase proteins are polymerase basic protein 1 (PB1), polymerase basic 
protein 2 (PB2) and polymerase acid (PA) (Noda et al., 2006; Boivin et al., 2010, Compans et al., 
1974). Finally a nuclear export protein/nonstructural protein 2 (NEP/NS2) is also present in the 
influenza A virion (Richardson and Akkina, 1991). 
 
 
1.5  Influenza A viral RNA (vRNA) and encoded Proteins 
The eight segments of negative single-stranded RNA of influenza RNA encode for 16 viral 
proteins (Shi et al., 2014). The viral RNA (vRNA) and proteins encoded by each segment and 
their functions are summarized in Table 1.1. 
The PB1 gene contains another two open reading frames encoding for the pro-apoptotic PB1-F2 
protein (Palese and Shaw, 2007) and the N40 (Wise et al., 2009). PB1-F2 is not an essential 
protein and is absent in some human and animal influenza A isolates (Chen et al., 2001), while 
the function of the N40 is unknown yet (Wise et al., 2009). Beside the PA protein, the PA 
segment encodes another three proteins, PA-X, PA-N155, and PA-N182 (Jagger et al., 2012, 
Muramoto et al., 2013). While PA-X was found to repress cellular gene expression, both PA-
N155 and PA-N182 are most likely involved in the replication cycle of the virus (Jagger et al., 
2012, Muramoto et al., 2013).  Segment 7, M gene, encodes for M1, M2, and M42, the second is 
a product of a spliced mRNA. Similarly, a spliced mRNA encodes for NEP/NS2 from segment 8, 
the NS gene (Lamb and Choppin, 1979, Lamb and Choppin et al., 1981).  
 
 
1.5.1 The RNA Polymerase Complex 
The subunits of the RNA polymerase, PB1, PB2, and PA are the largest proteins encoded by 
longest vRNAs. The three subunits form a compact structure (Area et al., 2004), which binds to 
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the vRNA.  Initially PB1-PA dimer binds to the vRNA, followed by PB2 binding to PB1 to form 
the trimeric complex (Deng et al., 2005). The polymerase complex is responsible for viral 
replication and transcription of the negative stranded viral RNA into mRNA.  
 
 
Table 1.1: IAV vRNA segments and encoded proteins. The nucleotide lengths of each gene 
are given based on the example A/Puerto Rico/8/34 virus (Palese and Shaw, 2007). 
Segment Nucleotides 
(nt) 
Amino Acid  
(AA) 
Encoded 
Protein 
Function 
1 2341 759 PB2 Component of RNA polymerase 
2 2341 757 PB1 
PB1-F2 
N40 
Component of RNA polymerase 
Pro-apoptotic activity 
Unknown 
3 2233 716 PA 
PA-X 
PA-N155 
PA-N182 
Component of RNA polymerase 
Repress cellular gene expression 
Involved in viral replication 
Involved in viral replication 
4 1778 550 HA Glycoprotein, receptor binding 
5 1565 498 NP RNA binding, synthesis, nuclear 
import 
6 1413 454 NA Glycoprotein, neuraminidase activity 
7 1027 
366 
252 
97 
M1 
M2 
M42 
Matrix protein, budding 
Ion channel activity, assembly 
Function can replace M2 
8 890 
418 
230 
121 
NS1 
NEP/NS2 
Multi-functional, IFN antagonist 
Nuclear export of RNPs 
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1.5.2 Hemagglutinin 
Hemagglutinin, HA is encoded by RNA segment 4, and deserved the name due to its ability to 
agglutinate erythrocytes from chicken, human, and guinea pig (Palese and Shaw, 2007). HA is a 
glycoprotein and the major surface antigen of the influenza virus providing the first contact 
between the virus and the host cell. In fact, HA is indispensable for binding of virions to, and 
fusion with the host cell. HA binds to the sialic acid receptor on the host cell. Fusion occurs 
when the precursor molecule of HA, HA0 is cleaved into HA1 and HA2 subunits, followed by 
conformation changes of the HA, fusion of the viral membrane with the cellular endosomal 
membrane, and subsequently uncoating of the virus (Klenk et al., 1975, Lazarowitz and Choppin, 
1975, Porter et al., 1979). The central factor of this process is the susceptibility of HA structure 
to pH changes, particularly low pH, which induces the conformational changes of HA.  This 
conformational change of the HA is a key activity, essential for the entire fusion process (Palese 
and Shaw, 2007). 
HA is a foremost determinant recognized by the adaptive immune system of the host. Mutations 
in the HA gene challenge the immune system of the host with continuously new antigens. The 
mutation rate of HA is about one base substitution in the HA gene per virus generation, which 
results in the high HA sequences variability and the several subtypes. Nevertheless, HA 
maintains its structure and function in all subtypes. The recognized subtypes of HA differ by at 
least 30% in the amino acid sequence of HAl and are therefore serologically not cross-reactive. 
Subtypes may include several variant strains, which are partially serologically cross-reactive 
(Webster et al., 1992).  
 
 
1.5.3 Nucleoprotein 
Nucleoprotein, NP, encoded by segment 5, plays an essential role in RNP trafficking across the 
nuclear membrane and therefore localize to the nucleus in early phase of viral infection, and to 
the cytoplasm in later phase. (Palese and Shaw, 2007). Although all RNP proteins possess a 
nuclear localization site (NLS), the NLS on NP is imperative for RNP nuclear import (Cros et 
al., 2005, O'Neill et al., 1995). NP was also shown to play a role in switching from replication in 
the early phase of infection to transcription towards the late phases of infection (Biswas et al., 
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1998, Poon et al., 1998, Mena et al., 1999). Finally, a recent study elucidated that IAV-induced 
apoptosis is mainly attributed to NP activity (Tripathi et al., 2013).   
 
 
1.5.4 Neuraminidase 
Neuraminidase, NA, encoded by vRNA segment 6, is a glycoprotein and the second major 
surface antigen of the virion. NA is essential in virus replication and virus spread. NA has 
enzymatic activity, which is to cleave terminal sialic acid/neuraminic acid receptor from the 
surface of the cell and from the virus particle causing the release of the progeny viruses from 
infected cell. Therefore, this function also facilitates the spread of progeny viruses to adjacent 
noninfected cells (Palese and Compans, 1976, Palese et al., 1974). NA is a highly mutable 
antigen. Variants of NA are selected in nature; this selection is partly a response to host immune 
pressure. These characteristics are responsible for the several NA subtypes, which are not 
serologically cross-reactive (Palese and Shaw, 2007). 
 
 
1.5.5 The M1 Protein 
Matrix protein M1 is the most abundant virion protein and is proposed to provide interaction 
between the glycoproteins and the RNPs (Nayak et al., 2004, Schmitt and Lamb, 2005). 
Furthermore, M1 interacts with the RNPs and NEP/NS2, which is believed to be essential in 
recruiting viral components to assembly site at the plasma membrane (Cros and Palese, 2003). 
Finally, M1 plays an essential role in viral budding process (Gomez-Puertas et al., 2000, Latham 
and Galarza, 2001). 
 
 
1.5.6 The M2 Protein 
Matrix protein M2 is an integral protein, which acts as an ion channel and therefore has a major 
function in completing the uncoating process of the virus during infection (Hay, 1992). Hereby, 
protons are channeled through from the exterior cellular endosomes to the interior core of the 
virus causing the dissociation of the RNP complex from the other viral components (Hay, 1992). 
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Furthermore, M2 channel activity may play a role in stabilizing the acid-sensitive HA subtypes 
H5 and H7 (Palese and Shaw, 2007). 
 
 
1.5.7 The NS Proteins 
NS1 (NS=non-structural) is a nuclear protein, which has an RNA-binding domain allowing for 
its interaction with several host factors, mainly those affecting the synthesis of interferon (IFN) 
mRNA. Therefore it is widely accepted that NS1 acts as antagonist for IFN (Palese and Shaw, 
2007).  
The NEP/NS2 was called earlier NS2, later nuclear export protein (NEP) due to its role in 
nuclear export of viral RNPs and because it was shown to associate with the M1 protein (O’Neil 
et al., 1998, Cros and Palese, 2003). 
 
 
1.6     Influenza Virus Replication Cycle 
1.6.1 Binding of the Virus to the Host Cell 
The infection of the host cell with the influenza virus starts with the binding of the viral HA 
glycoprotein to the cellular sialic acid receptor on the host cell surface. This, in fact, is the step, 
which distinguishes human pathogens from avian pathogens. HA of human influenza A 
pathogens bind to sialic acid, which is attached to penultimate galactose by an α 2,6 linkage, a 
condition found in human tracheal epithelial cells (Couceiro et al., 1993, Connor et al., 1994). 
HA of avian pathogens bind to sialic acid, which is attached to penultimate galactose by an α 2,3 
linkage, a condition found mainly in the gut epithelium of ducks (Couceiro et al., 1993, Connor 
et al., 1994). This binding activity however, can change in case of specific mutations in the HA 
gene (Gambaryan et al., 1999). 
 
 
1.6.2 Entry and Uncoating of the Virus 
Entry of IAV occurs via internalization by endocytic compartment. The low pH of the endosome 
causes the cleavage of the HA molecule into HA1 and HA2, accompanied by conformational 
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changes of HA, which activates the fusion of the viral membrane with the endosome. 
Simultaneously, the M2 channel protein allows the influx of proton ions from the endosome into 
the virus causing acidification, which disrupts the interaction between M1 and the RNPs (Lamb 
et al., 1994). The intensive structural changes of several HA molecules open up a pore and in a 
process called uncoating, the virus release its vRNPs into the cytoplasm (Lamb et al., 1994). 
 
 
 
 
 
Figure 1.2: Illustration on influenza A replication cycle. IAV binds to the sialic acid receptor, 
followed by its entry via endocytosis, fusion between the endosome and the viral membrane, 
which results in viral uncoating. Thereafter, RNPs are transported to the nucleus, where 
transcription and translation from the vRNA molecules take place. Both mRNA and the newly 
synthetized vRNA in from of RNPs are exported to the cytoplasm, where viral proteins are 
expressed and directed with the RNPs to the assembly site, packaged into new viruses followed 
by budding out of the cell (Palese and Shaw, 2007).     
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1.6.3 Viral Transcription and Replication 
Although it is well established that RNA viruses replicate in the cytoplasm, influenza is the 
exception. All viral RNA synthesis occurs in the nucleus, therefore trafficking of the vRNAs 
between cytoplasm and nucleus underlies a strict regulation. The NP, which coats the vRNAs 
possess NLS and is responsible for the import of the vRNAs into the nucleus (Cros & Palese, 
2003, Cros et al., 2005, O'Neill et al., 1995).  
In the nucleus, the viral polymerase complex uses the negative stranded vRNAs as a template for 
transcription and for replication, both result in the syntheses of positive stranded RNAs, mRNAs 
(transcription) and complementary RNAs (cRNAs) (replication). cRNAs are full-length copies of 
the vRNA, while mRNAs are the capped and polyadenylated incomplete copies of the vRNA 
(Neumann et al., 2004). The process behind the capping and polyadenylation of the mRNA is 
very interesting. Capping of the viral mRNA depends on the activity of cellular RNA polymerase 
II (Englhardt et al., 2005). In a process known as “cap snatching”, the viral polymerase complex 
molecule PB2 binds to the 5’-cap structure of a newly capped cellular RNA and the PA steels it 
with additionally 10-13 nucleotides using its endonuclease activity. The viral polymerase uses 
this “snatched” capped molecule as a primer for the viral mRNA (Blaas et al., 1982a, Blaas et al., 
1982b, Ulmanen et al., 1981, Dias et al., 2009). Polyadenylation occurs when the viral 
polymerase stutters towards the end of the synthesis of the positive strand RNA at the 
complementary stretch of uridine nucleotides located at the 5’ end of the vRNA, which result in 
synthesis of 3’ poly A tail (Luo et al., 1991, Li and Palese, 1994, Poon et al., 1999). These 
mRNAs serve as templates for viral gene expression, while cRNA are used as templates for 
replication producing vRNAs. Although the switch between transcription and replication is not 
fully understood, it is widely accepted that the nucleoprotein (NP) plays a major role in 
switching from transcription in the early phase of infection to replication in the late phases of 
infection (Biswas et al., 1998, Poon et al., 1998, Mena et al., 1999).   
Newly synthetized mRNAs export to the cytoplasm takes advantage of cellular mechanisms for 
translation into viral proteins. Newly synthetized subunits of the polymerase complex and NP are 
imported into the nucleus via their NLS to catalyze the process of replication and transcription 
(Jones et al., 1986, Neumann et al., 1997). At the end of the replication, the negative stranded 
vRNAs are produced, bind to the polymerase complex, and get coated by the NPs. These newly 
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synthetized vRNPs get exported to the cytoplasm. This translocation is attributed to the function 
of the matrix protein M1 and NEP/NS2, in correlation with cellular export receptor CRM1 
(O’Neill et al., 1998, Akarsu et al., 2003, Cros and Palese, 2003, Brunotte et al., 2014). 
Interestingly, also cRNAs bind to polymerase complex and NPs forming cRNPs, these molecules 
however, do not get exported into the cytoplasm. The reason behind this discrimination lies 
within the specific conformation assumed by the viral polymerase while interacting with the 10th 
Adenine nucleotide on the 5’ of the vRNA (Tchatalbachev et al., 2001).  The debate on whether 
vRNPs are exported individually or as vRNP bundle goes on (details are summarized in Giese et 
al., 2016).  
 
 
1.6.4 Viral Assembly 
Upon synthesis of viral proteins from the recently exported viral mRNA, viral glycoproteins HA, 
NA, and M2 are subjected to biochemical modifications, glycosylation (HA and NA), 
palmitoylation (HA and M2), and folding on the endoplasmic reticulum and the Golgi apparatus 
(Doms et al., 1993, Veit et al., 1991). The three glycoproteins contain apical sorting signals 
located in their transmembrane domains, which enables their association with cellular lipid rafts 
and their transport to the assembly site on the apical plasma membrane (Barman et al., 2001, 
Barman and Nayak, 2000, Lin et al., 1998). There, they accumulate on the polar surface of the 
plasma membrane, exactly where virus budding takes place (Rodriguez and Pendergast, 1980). 
The trafficking of the remaining viral proteins to the assembly site is not well established yet, 
however, different experimental sets suggest that M1 is the main actor in this process (Gomez-
Puertas et al., 2000, Palese and Shaw, 2007).   
Exported vRNPs accumulate in a juxtanuclear site close to the microtubule-organizing center 
(Chou et al., 2013, Eisfeld et al., 2011, Amorim et al., 2011, Amorim et al., 2013) and 
endosomal-recycling compartment (ERC) (Kawaguchi et al., 2015). Subsequently, vRNPs are 
actively transported to the apical plasma membrane along microtubules via ERC derived 
transport vesicles, which are loaded with Rab11GTP, to which vRNPs are bound (Kawaguchi et 
al., 2015, Momose et al., 2011). 
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1.6.5 Viral Packaging  
The vRNPs and the viral structural proteins are assembled at the apical plasma membrane in 
viral budozone (Schmitte and Lamb, 2004). Different studies showed that the presence of all 
eight assembled vRNA, associated as genome bundle in the viral budozone, is indeed the trigger 
for the formation and release of progeny viruses (Giese et. al., 2016). During genome packaging, 
M1 function as an adapter, which connects vRNPs to the budding viral membrane (Giese et. al. 
2016).  Furthermore, internal regions within vRNAs were accredited an essential role in genome 
packaging (Gavazzi et al., 2013). 
 
 
1.6.6 Budding and Release 
It is widely accepted that sequences at the 3’ and 5’ ends of each vRNA (Goto et al., 2013, 
Hutchinson et al., 2010) function as packaging signals prerequisite for the insertion of the vRNPs 
in the budding particles (Neumann et al., 1994, Goto et al., 2013). In fact, different researchers 
utilized this property to develop systems studying influenza virus promoter (Neumann et al., 
1994, Flick et al., 1996, Flick et al., 1999, Azzeh et al., 2001, Tchatalbachev et al., 2001). It is 
also proposed that M2 cytoplasmic tail mediates vRNPs incorporation into the budding particle 
(McCown and Pekosz, 2005). Budding starts with the fusion at the base of the budding site, 
where enveloped progeny viruses are released by scission from the cell membrane, a process 
mediated by M2, which is located at the lipid raft periphery (Zhang et al., 2000, Leser and Lamb, 
2005, Rossman et al., 2010). Some studies demonstrated that specific mutations in the M2 
protein impair both, the production of infectious virions and the release of virions (Cheung et al., 
2005, Iwatsuki-Horimoto et al., 2006, McCown and Pekosz, 2006, Rossman et al., 2010). 
Different cellular factors are also involved in this budding process (Gorai et al., 2012).  
The final step in the IAV life cycle is the release form the host cell. This is the time point, when 
the enzymatic activity of glycoprotein NA comes into action. NA removes, to be more exact, NA 
cleaves sialic acid off both host cell surface as well as virions’ glycoproteins, preventing HA 
from interaction with the sialic acid receptor and paving the way for the actual release of progeny 
viruses (Palese and Shaw, 2007, Wright et al., 2007). Therefore, null NA mutation or specific 
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mutations in the NA gene may result in virion aggregation on the host cell surface (Wright et al., 
2007).  
IAV progeny viruses can now start infecting adjacent cells causing cell death to the infected 
ones. As a matter of fact, IAV induces apoptosis by activating transcription factors involved in 
the expression of cytokines and chemokines (Brydon et al., 2005, Palese and Shaw, 2007). In 
contrary to the assumptions, apoptosis does not lead to an antiviral effect on IAV; it rather serves 
IAV spread and survival (Palese and Shaw, 2007). Viral protein NS1, M1, M2, and PB1-F2 were 
shown to play a role in viral induced apoptosis; however, a recent study demonstrated that NP is 
the major actor in IAV-induced apoptosis (Tripathi et al., 2013). 
 
 
1.7  IAV Promoter Activity and Reverse Genetics  
Each vRNA segment contains noncoding regions at both 5′ and 3′ ends, a part of which is 
segment specific (Zheng et al., 1996), however, 13 and 12 nucleotides at the terminal ends of the 
5’ and the 3’ are conserved among all segments, respectively.  Both ends are necessary for the 
activity of the vRNA promoter. Different models were proposed to illuminate the base pairing 
between the 5’ and the 3’ ends and/or base pairing within each end as hairpin loops, critical for 
the promoter activity (reviewed in Palese and Shaw, 2007). Nevertheless, a very recent study 
provided evidence in favor of the corkscrew model proposed by Flick et al. (1996, 1999) by 
using a sophisticated FRET assay and providing a 3D structural information (Tomescu et al., 
2014). The cRNA promoter is complementary to the vRNA promoter and is essential for the 
replication and the production of vRNAs. Also here, a Corkscrew configuration initially 
proposed by Azzeh et al. (2001) is necessary for the function of the cRNA promoter (Crow et al., 
2004). Neumann et al. (1994) developed one of the successful genetic systems to study IAV 
vRNA and cRNA promoter activities, exploiting the reverse genetics of the influenza virus to 
express foreign genes.  Hereby, the HA gene coding region was replaced by a chloramphenicol 
acetyltransferase, inserted in vRNA antisense orientation, while maintaining the conservative 
terminal sequences at the 5’ and 3’ ends. In vivo experiments showed that this acetyltransferase 
segment was packaged into progeny virions (Neumann et al., 1994). Furthermore, this system 
utilizing IAV reverse genetics was also implemented to express two genes simultaneously by 
inserting them in bicistronic, ambisense manner (Azzeh et al., 2001). Hereby, the vRNA 
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promoter expressed one of the genes, while the cRNA promoter expressed the second one, 
respectively (Azzeh et al., 2001).  All of these models and approaches had been useful genetic 
tools to study viral protein functions and IAV infection mechanisms, and also to generate 
vaccines strains and viral vectors against other human diseases.    
 
 
1.8  IAV Evolution and Genetic Diversity 
Wild aquatic birds are the main reservoir of influenza A viruses.  Indeed, molecular biology, 
bioinformatics, and phylogenetic studies revealed that all mammalian IAVs are derived from 
avian IAV (Webster et al., 1992).  While IAV seems to be relatively in an evolutionary 
equilibrium in wild aquatic birds, it rather changes in incessant manner in mammalian and 
poultry, which is partially attributed to host immune pressure.  However, the evolutionary rate 
among the different IAV segments is not equal.  A good example is the HA gene subtype H3.  
Evidently, the human H3 (HA gene) is changing at a rate much faster than that for other IAV 
segments with a mutation rate of 4X10-3 substitutions per nucleotide per year and 5X10-3 amino 
acid changes per residue per year (Webster et al., 1992).  43% of the changes induce amino acid 
exchanges, most of which localize at the antigenic sites of H3.  This is actually the reason why 
H3N2 component of the seasonal vaccine is exchanged more often than other virus strain 
component (Fan et al., 2004, Wright et al., 2007). 
The genetic changes of influenza A virus are mainly introduced by at least three evolutionary 
mechanisms, antigenic drift (point mutations), genetic shift (gene reassortment), and/or RNA 
recombination. 
 
 
1.8.1 Antigenic Drift 
Spontaneous point mutations in the HA and NA genes causing antigenic changes in HA or NA 
proteins are referred to as antigenic drift. The lack of RNA polymerases proofreading contributes 
to replication errors in the order of 1 in 104 bases (Holland et al., 1982, Steinhauser and Holland, 
1987).  In vitro experiments revealed that this process is the result of positive selection by 
neutralizing antibodies in mammals and subsequently prevents antibodies against the parental 
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strains from recognizing the new drifted mutants (Webster and Laver, 1980).  Although rather 
rare, antigenic drift can also occur in poultry strains.  Drifted IAV mutants circulate for 2-5 years 
and can cause epidemics, but not pandemics (Wright et al., 2007).  
 
 
1.8.2  Antigenic Shift 
In a process called reassortment, the segmented genome of two IAV co-infecting a cell can 
exchange and produce a novel gene combination (Desselberger et al., 1978).  Antigenic shift is 
caused by the reassortment of the influenza A viral segments, which occurs mainly when human 
and animal strains, different human strains, or different avian strains co-infect a cell.  The 
consequences of this genetic combination are new HA or NA subtypes, which results in high 
infection rates and confers pandemics potential. The 2009 swine-origin H1N1 pandemic, 
A(H1N1)pdm09 in humans, known as swine flu, was a result of an antigenic shift event between  
swine influenza A strains (Morens and Taubenberger, 2009, Garten et al., 2009). Antigenic shift 
can also be the result of the transmission of an avian or swine influenza virus to human.  In fact, 
it is widely accepted that the Spanish Flu was caused by antigenic shift as the result of the 
transmission of an avian-like influenza strain derived in toto from an unknown source, which 
was ultimately avian, to human (Azzeh et al., 2001, Melkonian et al., 1999, Mindich, 2004, 
Mjaaland et al., 1997, Mochalova et al., 2003, Paragas et al., 2001, Park et al., 2003). The reason 
for the high infection rates and pandemics resulting from the antigenic shift is the naïve immune 
system, which was not exposed to the new antigens of HA and/or NA. 
 
 
1.8.3  RNA Recombination 
Beside antigenic shift and drift, influenza A virus segments can undergo recombination events. It 
was believed that such events are rare, however the identification of recombinant viruses in the 
recent years proves the opposite. RNA recombination produces low biologically fit viruses; 
selective pressure may however, provide selective advantages (Wright et al., 2007).  
A/seal/Massachusetts/1/80 and A/turkey/Oregon/71 are examples of recombination, where lower 
pathogenic strains are transformed into highly pathogenic strains.  In both cases, an insertion of 
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about 60 nucleotides in the HA gene enhanced cleavability of the HA and consequently its 
biological fitness (Khatchikian et al., 1989, Orlich et al., 1994).  
 
 
1.9  IAV Host and Subtypes 
Different influenza A subtypes infect a wide range of mammals and birds.  IAV is classified into 
subtypes according to the antigenic composition of their hemagglutinin (HA or H) and 
neuraminidase (NA or N) glycoproteins on the viral envelope (Wright, 2000). By September 
2016, eighteen different hemagglutinin subtypes and 11 different neuraminidase subtypes were 
identified (CDC 2016 Flu website). 
 
 
1.9.1  IAV in Human  
The first record of human infection with influenza A was in 412 BC by Hippocrates (Harris et 
al., 1919).  Although nine IAV pandemics occurred before the “Spanish flu” (Morens et al., 
2010b), only the subtype of the later was retrieved (see below). Influenza A subtype H1N1 was 
responsible for the “Spanish flu” in 1918/1919 and with the exception of human infections with 
avian strains, all pandemics ever since were caused by descendants of that H1N1 (Taubenberger 
and Morens, 2006).  
Subtypes H1N1, H2N2, and H3N2 are the major subtypes attributing to infections in humans 
ever since 1918  (Wright et al., 2007, Taubenberger and Morse, 2006, Wahlgren, 2011). 
Subtypes H1N1 and H3N2 are the major types circulating among humans and had therefore been 
an essential component of the seasonal influenza vaccine (WHO, FluNet 2016). Despite strict 
species barriers, the isolation of H5N1 avian influenza in a young boy in Hong Kong in 1997 
marked the first human reported spill-over infection (de Jong et al., 1997, Shortridge et al., 1998, 
Wright et al., 2007, Liu et al., 2013, Taubenberger and Morse, 2010). Ever since, many cases of 
human spill-over infections with avian influenza strains, H5N1, H7N9, H7N7, H7N3, H7N2, and 
H9N2 were reported from all over the world (Belser et al., 2009, Liu et al., 2013, Taubenberger 
and Morse, 2010, Wang et al., 2016). Fatalities were highest in case of H5N1 infection 
(Shortridge et al., 1998, Liu et al., 2013).  
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1.9.2  IAV Subtypes in Swine and other Mammals 
Influenza A virus infects different mammalian species, however, swine plays a major role in the 
emergence of pandemic IAV.  This is due to biological properties of swine’s tracheal epithelial 
cells, as these have the sialic acid receptors, which can bind both, human and avian IAV (Ito et 
al., 1998). This property enables the propagation of avian and human IAV in pigs, which can 
undergo reassortments resulting in new unpredictable IAV strains.  The symptoms and clinical 
features of IAV infection in swine are similar to those in human. Although the reassortment 
tendency is not equally high, it can occur between swine strains, swine and avian strains, or 
human and avian strains.  Reassortment between avian-human and swine IAV resulted in a fatal 
IAV variant (Claas et al., 1994).  Despite that it is well established that the 1918/1919 “Spanish 
flu” is an avian derived, HA and NA gene sequences were closely related to the A/swine/Iowa/30 
virus (Taubenberger, 2006).  Indeed, the H1N1 Spanish flu in 1918/1919 also infected pigs back 
then and is still circulating (Wright et al., 2007).  Both, human-like H3N2 and H1N1 as well as 
an avian-like H1N1 were isolated from pigs (Wright et al., 2007).  Reassortants such as H1N2 
(from swine H1N1 and human H3N2), H3N2 (triple reassortant from human, avian and swine or 
double; human and swine) were also isolated from swine in different parts of the world.  Finally, 
A(H1N1)pdm09 also originated from swine  and was not the first swine H1N1 isolated in 
human.  All these facts make the swine a very critical host for IAV and a dangerous, evidently 
unpredictable source of pandemics (Wright et al., 2007).   
As for other mammals, H7N7 and H3N8 were isolated from horse, H7N7, H3N2, and H4N6 
were isolated from seals, H13N2 and H13N9 were isolated from lungs of a whale, H10N4 was 
isolated from Minks, and H5N1 was isolated from cats, dogs and a tiger, (Wright et al., 2007, 
Buttler, 2006).  
 
 
1.9.3  Avian Influenza A  
The first record in history of avian influenza was documented in 1878 in Italy and termed “fowl 
plaque”.  Wild birds and waterfowl are the natural reservoir for all subtypes of influenza A 
(Wright et al., 2007, Peiris et al., 2007), with the exception of the bat subtypes H17N10 and 
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H18N11 (Shi et al., 2014).  More than 105 IAV species had been isolated from 26 different 
families of birds and almost all isolates came from the families Anseriformes (ducks, geese, 
swan) and Charadriformes (gulls, terns, surfbirds, sandpipers) (Wright et al., 2007). The 
infection of aquatic birds with influenza A viruses is typically asymptomatic, which indicates an 
optimal adaptation of these viruses to their host. Avian viruses replicate mainly in the intestinal 
tract and infected avian species shed influenza viruses in high concentrations in feces (Webster et 
al., 1978).  Fecal contaminated water reservoirs; such as lakes is therefore a major transmission 
route of IAV among birds.   
Although IAV infections in birds occur in the intestine, few exceptions were observed.  IAV 
infection was established in respiratory tract of ducks and turkeys, either because they were 
infected with human IAV strains or by a drifted virus type, which caused a mutation in the HA 
gene, allowing its binding to the sialic acid in the epithelial cells of the respiratory tract. An 
example of this was observed chicken in 1983, when a highly pathogenic H5N2 lost its HA 
glycosylation site, exposing HA cleavage site to different cellular proteases and causing the 
infection of the virus to epithelial cells other than the intestine (Freed, 2002).  
Antigenic drift is limited in aquatic birds and more pronounced in domestic poultry.  With few 
exceptions, aquatic birds are not susceptible to highly pathogenic avian influenza (HPAI), 
whereas HPAI outbreaks in chicken can result in up to 100 mortality rates, which repeatedly 
occurred with different HPAI H5N1 strains causing endemics in poultry all over the world 
(Wright et al., 2007, Wang et al., 2016). 
Numerous influenza A subtypes infect birds, most fatal avian influenza outbreaks were caused 
by H5N1, H7N3, H7N7, H7N9, H7N4, H7N2, H7N1, H5N2, H5N8, H5N9, H5N3 (Wright et al., 
2007, Alexander, 2007, Wang et al., 2016). 
 
 
1.10  Influenza A Pandemics  
According to historical and medical records, influenza virus caused nine pandemic outbreaks 
between 1510 and 1893 (Taubenberger and Morens, 2009, Morens et al., 2010b).  Efforts  made 
to identify the subtype causing the last outbreak in the 19th century, which spanned 1889-1893, 
known as the “Russian flu”, concluded that the influenza subtype must be an H3 (Dowdle, 1999).   
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The 10th pandemic occurred early in the 20th century, the well-known “Spanish flu” in 
1918/1919, which caused death to more than 50 million people worldwide and infected one third 
of the world population at that time (Taubenberger and Morens, 2006).  Serological analysis 
from survivors’ sera in the 1930s suggested that the causative influenza subtype for this 
pandemic was an H1N1, closely related to swine influenza (Shope, 1936, Philip and Lackman 
1962, Dowdle 1999).  It was not until the end of the 20th century and the beginning of the 21st 
century when the causative subtype H1N1 was confirmed (Reid et al., 1999, Reid et al., 2000).  
Herby, archived and autopsy tissues from the pandemic of 1918/1919 in the USA and England 
served as specimen to determine the sequences of the causative influenza A subtypes exploiting 
the modern techniques of molecular biology and bioinformatics (Reid et al., 1999, Reid et al., 
2000, Basler et al., 2001, Reid et al., 2002, Reid et al., 2003, Reid et al., 2004, Taubenberger et 
al., 2005).  All of these studies also concluded that the 1918/1919 H1N1 did not have a swine 
origin, despite amino acid similarities to swine virus, but was rather an avian derivation 
(Taubenberger 2006).    
The second pandemic in the 20th century occurred in 1957-1958, originated in Southeast Asia 
and was caused by H2N2 subtype (Scholtissek et al., 1978).  The third pandemic was in 1968, 
originated in Hong Kong and was caused by H3N2 subtypes, whereas the fourth and last 
pandemic of the 20th century occurred in 1977-1978, starting in China and spreading to Russia 
and was caused by H1N1 (Taubenberger and Morens, 2009).     
The first influenza A pandemic of the 21st century occurred in 2009 and was caused by a swine-
origin H1N1 (Morens and Taubenberger, 2009, Garten et al., 2009).  The pandemic of 2009, 
which started in Mexico and the USA, caught the world by surprise and prompted the WHO to 
raise the level of pandemic alert to phase 6.  Worldwide, the 2009 H1N1 pandemic caused 
infections to millions of people and resulted in at least 16,813 deaths (WHO, 2010).  
 
 
 1.11 Clinical Features of Influenza A Infection in Human 
Infection with influenza A viruses among humans may result in mild symptoms, severe 
symptoms, or may cause a rather complicated disease with fatal outcome.  The typical mild 
symptoms are the common headache, runny nose, nasal obstruction, chills, dry cough and fever. 
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Symptoms may however develop to cause rather clinical manifestation such as myalgias, 
malaise, anorexia, soreness, pharyngeal inflammation, viral pneumonia, and conjunctivitis.  
Patients may recover from the primary viral pneumonia; however, combined viral-bacterial 
pneumonia is common with fatality rates depending on the type of bacteria (reviewed in Wright 
et al., 2007).  
Infection in children may be accompanied by febrile convulsions, otitis media, croup, and result 
in quite higher demand on pediatrician consultations and hospitalization (Wright et al., 2007). 
The severity of infection with IAV depends on the strain of the virus subtype, dose of the virus 
and the status of the host immune system.  For example, despite high pathogenicity of the 
1918/1919 H1N1 virus, most infections occurred in the younger age group 20-40 years and most 
fatalities were among those below the age of 65 years (Simonsen et al., 1998).  Scientists 
proposed that the older generation might have contacted antigens composing the H1N1 towards 
the end of the 19th century, which provided partial protection in this age group (Simonsen et al., 
1998, Taubenberger et al., 2001).   
 
 
1.12  Diagnosis of Influenza A Infection 
The most convenient and reliable diagnosis of influenza infection is molecular biology testing of 
the viral RNA using the reverse transcriptase polymerase chain reaction (RT-PCR).  RT-PCR is 
also optimal for sequencing and mutational analyses, including testing drug resistance.  Rapid 
testing such as direct immunofluorescence (DFA), rapid molecular biology test, and antigen 
testing are convenient in clinics, but they are neither sensitive nor specific.  Therefore, it is 
advised to confirm results using RT-PCR.  Viral culture could be applied in specific cases, but is 
not a generally used approach. The specimen used in all testes intended for influenza diagnosis is 
Nasopharyngeal aspirate (NPA) (CDC Flu Website, 2016).  
 
1.13   Vaccines against Influenza Virus 
Two types of influenza vaccines are available, the inactivated form of the virus, given as a 
trivalent or quadrivalent injection given intramuscularly (IM), and the live attenuated 
quadrivalent, given as a nasal spray. 
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1.13.1  Inactivated Influenza Vaccine 
The inactivated vaccine contains inactivated non-replicating virus cocktail of two influenza A 
and one influenza B (trivalent), or additionally a second influenza B virus strain (quadrivalent).  
The influenza A vaccine typically includes circulating H1N1 and H3N2 subtypes, and circulating 
influenza B strains.  The viruses are prepared in embryonated chicken eggs and therefore the 
vaccine contains egg-derived proteins, formaldehyde (used during the preparation of the vaccine) 
and preservative thiomersal.  These three components had been continuously criticized especially 
during the 2009 pandemic. Healthy individuals older than 2 years can be vaccinated with the live 
attenuated vaccine, which does not contain egg proteins, see below.  Also, a cell culture-based 
inactivated vaccine had been approved in different countries (Flucelvax, Seqirus, Holly springs, 
North Carolina).  Regarding thimeresol, recent vaccines had been manufactured without 
thiomersal (Fluzone Quadrivalent, Sanofi Pasteur, Fluarix Quadrivalent, GSK), while in another 
vaccine, Fluad (Seqirus, Holly springs, North Carolina) thiomeral was replaced by a new 
adjuvant, MF-59 (CDC 2016 Flu website). 
In contrast to many other vaccines, the viruses in influenza vaccines have to be evaluated and 
updated frequently due to the rapid appearance of HA-escape mutants in human populations. For 
example, variability of the H3N2 subtype has required 19 changes in the vaccine component 
over 29 years (Hay et al., 2001), and ever since the 2009 pandemic, the H1N1 component of the 
vaccine had been the (H1N1)pdm09-like virus.                                                                                                                                                                                                                                                                                             
An international committee determines the recommendation for composition of the vaccine 
annually taking the circulating subtypes into consideration. GISRS is a global public health 
laboratory network coordinated by WHO, currently consisting of 143 National Influenza Centers 
(NICs) in 113 WHO Member States, 6 WHO Collaborating Centers for Influenza (CCs), 4 WHO 
Essential Regulatory Laboratories (ERLs) and 13 WHO H5 Reference Laboratories. The USA 
Advisory Committee on Immunization Practices (ACIP) also gives recommendation on the 
composition of the influenza vaccine cocktail (ACIP, 2015).  WHO as well as ACIP 
recommends that influenza vaccines in the 2016-2017 season in northern and southern 
hemisphere influenza season contain the following viruses:  
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 A/California/7/2009 (H1N1)pdm09-like virus 
A/Hong Kong/4801/2014 (H3N2)-like virus 
 B/Brisbane/60/2008-like virus.  
Quadrivalent vaccines includes an additional influenza B virus strain, a B/Phuket/3073/2013–
like virus (WHO FluNet, 2016 ). 
 
 
1.13.2   Live Attenuated Vaccine 
Live attenuated influenza vaccine (LAIV) is produced by reverse genetics using the HA and NA 
genes from circulating viruses on an attenuated, temperature-sensitive, cold adapted virus 
backbone.  LAIV is administrated intranasal and is known as nasal spray flu vaccine.  The 
current LAIV vaccine is a quadrivalent and contains an H1N1, H3N2, and two influenza B 
viruses (Yamagata and B Victoria) (Quadrivalent, MedImmune and AstraZeneca).  LAIV is 
licensed in different countries, though the target group differs.  In the US, LAIV is recommended 
for children from two years up to adults at the age of 49.  The recommendation in Canada is 
similar but spans to the age of 59, whereas LAIV is generally limited to age group 2-18 in 
Europe.  LAIV is not recommended for children below two years of age, elderly, pregnant 
women and immunocompromised people.  One dose of LAIV is recommended for vaccinees 
with previous vaccination history, while two doses are recommended for immunologically naïve 
subjects.  LAIV is an advantage for healthy individuals, who have allergy to eggs, as it is not 
developed in eggs.  For the season 2016-2017, the CDC did not recommend LAIV (CDC 2016 
Flu website), due to poor efficacy against H1N1 and H3N2 in season 2015-2016.  
 
 
1.13.3   Vaccine Efficiency  
Vaccines against matched influenza virus strains can reduce the duration and severity of illness 
in 60 to 80% of healthy adults.  The rate of protection is lower in groups at higher risk of disease, 
such as the elderly and immunocompromised individuals.  Furthermore, vaccination may not 
provide protection against strains, which unexpectedly infect human such as the H5N1 strains 
(Wright et al., 2007). 
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An example of failing efficacy of the annually prepared influenza vaccine was encountered in the 
2009 pandemic. In fact, (H1N1)pdm09 pandemic flaunted the vulnerability of the health 
institutions worldwide, when unexpectedly a virus with such a high pathogenicity makes its way 
among immune naïve population.  The huge medical advances human had made in the last years 
may have not helped predicting the pandemic, but made the production of a new vaccine within a 
very short period possible.  
An example of low efficacy was observed in the season 2014-2015, the season of this study.  The 
vaccine efficacy in the USA was as low as 23% (Flannery et al., 2015).  The most common 
H3N2 subtype circulating during the season 2013-2014 was A/Texas/50/2012 and was therefore 
recommended and included in the vaccine cocktail of the season 2014-2015.  However, infection 
with influenza A virus in the 2014-2015 season had been mainly attributed to the H3N2 
A/Switzerland/9715293/2013 lineage.  As a consequence A/Switzerland/9715293/2013 was 
recommended and included in the vaccine cocktail for the season 2015-2016 (WHO FluNet 
2016, CDC 2016 Flu website). 
 
 
1.13.4 Vaccine Composition for the 2014-2015 season 
The samples in this study were collected in the season 2014-2015. The composition of the 
influenza vaccine for both, live and inactivated (WHO Flunet, 2014) for that season was:  
A/California/7/2009 (H1N1)pdm09-like virus 
A/Texas/50/2012 (H3N2)-like virus 
B/Massachusetts/2/2012-like virus. 
 
 
1.14 Antiviral Therapy 
Currently available antiviral therapies against influenza are based on two categories, the category 
of M2 blockers and that of Neuraminidase inhibitors.  Drugs of both categories are approved for 
adults and children ≥ 1 year old.  The key for successful therapy for both categories is the early 
administration of the drugs (Wright et al., 2007, Takashita et al., 2015b). 
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Several antiviral drugs against influenza A are in clinical trials or in pre-clinical development 
and target the activity of other influenza proteins such as the viral polymerase complex, the NS1 
protein, and hemagglutinin (reviewed in Naesens et al., 2016). 
 
 
1.14.1  M2 Blockers 
Amantadine hydrochloride and Rimantadine, an analog of amantadine, are efficient against all 
subtypes of IAV (Wright et al., 2007).  Both inhibit virus replication by blocking the ion channel 
activity of the M2 protein and thus blocking the flow of H+ ions from the acidified endosome 
into the interior of the virion, which subsequently inhibits the release of the RNP into the 
cytoplasm (Hay, 1992).  
Amantadine and Rimantadine are useful for prophylaxis against H1N1, H2N2, and H3N2 IAV 
infections in adults and children.  Optimally, Amantadine is administrated with the onset of first 
symptoms of influenza infection. During an epidemic involving influenza A H1N1 and H3N2 
viruses, Amantadine and Rimantadine protect against influenza-like illness (78% and 65%, 
respectively) and limit the spread of influenza A infection (Wright et al., 2007). 
 
 
1.14.2  Neuraminidase Inhibitors 
Zanamivir [Relenza] is a specific inhibitor of the neuraminidase (NAI) of all influenza A and B 
viruses.  Zanamivir must be administered intranasal or inhaled for optimal effect.  An additional 
neuraminidase inhibitor is the well-known Oseltamivir [Tamiflu], which can be taken orally. 
Both drugs inhibit the activity of neuraminidase by blocking the cleavage of budding virus, 
which subsequently cause aggregation of progeny viruses, limiting their release and spread.  
Permavir and Laninamivir Octanoate, analogues to Zanamivir and Oseltamivir, were approved 
recently in some countries (Naesens et al., 2016).  
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1.14.3 Resistance to Antiviral Therapy 
The incidences of resistance to antiviral therapies against influenza A emerged with the 
increasing use and overuse of Tamiflu during and after the 2009 pandemic.  Belanov et al. (2015) 
identified 40 mutation sites in influenza A(H1N1)pdm09 and 32 in A(H3N2) strains in 
comparison to vaccine strains A/California/07/2009(H1N1) and A/Brisbane/10/2007(H3N2), 
respectively.  These mutations were called evolutionary markers, because they resulted in amino 
acid changes, which were maintained in influenza proteins for a relatively long time.  Only few 
of these markers are present in vaccine strains recommended by the WHO for 2015/2016.   
Histidine to tyrosine substitution at residue 274 (H274Y in N2), or residue 275 (H275Y in N1) is 
the most common mutation conferring a high level of resistance to oseltamivir (Gubareva et al., 
2002). H275Y mutation has been documented as a genetic marker of resistance to oseltamivir 
among patients with either seasonal influenza A H1N1 or influenza A H5N1 virus infections (de 
Jong, 2005). 
The main mutations responsible for oseltamivir resistance in H3N2 subtype are R292K and 
E119G/D/A/V.  N294S mutation in N2 (N295S in N1) was also shown to be responsible for 
partial resistance to oseltamivir in H3N2 and H5N1 subtypes (Kiso et al., 2004, McKimm-
Breschkin, 2000). 
L26F, V27A, A30T, S31N and G34E mutations in the M2 protein of influenza viruses account 
for Amantadine and Rimantadine resistance and are also found in recent human A H3N2 (Wright 
et al., 2007). 
 
 
1.15 Importance of Subtyping and Genetic Analysis of Circulating Influenza Viruses 
As clearly illuminated in 1.13 above, subtyping and sequence analysis of circulating influenza 
viruses is indispensible for the annual vaccine recommendation and beyond.  Sequence analysis 
reveals whether the virus is identical, related or unrelated to previously circulating strains.  
Catching up with the continuous changes in the HA and NA genes had been and will always be 
prerequisite for previous, current, and future planes for vaccine and drug development against 
influenza viruses. 
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Worldwide, substantial efforts had been made to keep up with circulating influenza viruses, 
which includes deep sequence analysis of the entire genomes of circulating viruses.  Despite this 
crucial role of sequencing circulating viruses, yet limited efforts had been made in the region as 
summarized below. 
 
 
1.16 Circulating Influenza A Viruses in the Middle East 
A survey of causative agents for acute respiratory infections among patients in Sudan in 2010–
2011 showed that 8.8% were attributed to influenza A virus, 75.7% were A(H1N1)pdm09, while 
21.6% were H3 subtypes (Enan et al., 2013). Sequencing analysis showed that H1 subtypes were 
related to several strains from around the world (USA, Japan, Italy, United Kingdom, Germany, 
Russia, Greece, Denmark, Taiwan, Turkey and Kenya), while H3 subtypes showed close 
similarity to strains from several parts of the world (Singapore, Brazil, Canada, Denmark, USA 
and Nicaragua) (Enan et al., 2013).  
In Tunisia, H3N2 and H1N1accounted for 56.25% and 32.5% of cases with influenza-like illness  
and acute respiratory infection during the 2008-2009 season, while in 2010–2011 season the 
circulating strains were predominantly the A(H1N1)pdm09 (70%) (El Moussi et al., 2013). 
A Lebanese study detected an outbreak in October 2009 caused by H1N1pdm strain which was 
closely related to a major A(H1N1)pdm09.  This strain had 4 mutations in the NA gene (V42I, 
N68T, N248D, and E462K) and 2 mutations in the HA gene: 1 in the Ca1 antigenic site (S206T) 
and 1 in the Ca2 antigenic site (D225E). All analyzed samples were amantadine-resistant, but 
none was zanamivir-resistant (Zaraket et al., 2011)  
Reports from Palestine in this regard are rare, Virology Research Laboratory (VRL) made initial 
efforts documenting the first detection of influenza A(H1N1)pdm09 back in 2009 (GI: 
260402483) and the outbreak of A(H1N1)pdm09 in 2013 (GI: 452816297). Nevertheless these 
reports were limited to single cases and did not resemble a real survey. 
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1.17   Research Significance 
Subtyping and sequence analysis of influenza A viruses are essential tools for the identification 
of circulating strains among Palestinians.  The knowledge gained in this regard is crucial for 
outbreak management, for determining the appropriate treatment, and for vaccine choices. 
Surveillances of influenza A subtypes and their genetic properties from different geographic 
regions can be used for tracking and prediction of virus evolution and for selection of vaccine 
strain candidates.  The objectives of this research are: 
 
1. To test the influenza A virus circulating in Palestinians over the influenza season 2015 using 
molecular techniques. 
2. To type influenza A by sequencing and bioinformatics analyses of the antigenic genes 
mentioned above. 
3. To compare retrieved Palestinian genotypes with regional and global ones. 
4. To verify the efficiency of the 2014-2015 seasonal influenza vaccine.  
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2. Material and Methods 
2.1    Study Population 
2.1.1  Criteria of Sample Collection 
Study population was Palestinian children and adults, who suffered mild to severe upper 
respiratory infection symptoms. Participants were either hospitalized (mainly Al-Makassed 
Islamic Charitable Hospital (MICH) in Jerusalem), attending medical private clinics (Ramallah, 
Bethlehem, and Nablus) kindergarten children (Jerusalem), or family members and friends 
(private, mainly from Jerusalem and Ramallah).  
 
 
2.1.2  Ethical Issues 
Al-Quds University ethical committee approved this study on children in 2014; approval was 
amended in 2015 to include adults and children (Appendix A). Every single participant signed a 
consent form before sampling, parents or legal guardians signed for children.  
Consent form (Appendix B) contained the following participants’ data: sex, age, residency, 
symptoms, hospitalized days, vaccination, and antibiotic administration. Additionally, consent 
form included questions, whether the participant was abroad, if yes when, and whether 
participant live near a poultry farm.  
 
 
2.1.3   Logistics of Sample Collection 
In order to organize and arrange sample collection, practical protocoled steps were planned and 
followed after agreements with hospitals, clinics and kindergartens. As for MICH, the protocol in 
place was to provide them with collection tubes; collection swabs along with consent forms, 
which were placed in fridges. Hereby a collection swab and consent form were attached to the 
collection tubes and placed on a stand at 4°C (fridge) at the pediatric and internal medical 
departments. After contacting hospital staff, samples and attached consent forms were collected 
regularly. In case of private clinics, the physician collected samples after guardians/parents 
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consent. On the very same collection day samples were transported to the laboratory. 
Kindergartens and private samples were collected by members of the Virology Research 
Laboratory and transported to the laboratory. Kindergartens were a special case in managing the 
logistics of consent. Kindergartens were provided with consent forms ahead of time, which they 
shared with the parents. Only those children with flu-like symptoms, whose parents consent, 
were subjecting to sampling.  
 
 
2.2 Collection of Nasopharyngeal Aspirate  
Nasopharyngeal aspirate (NPA) were collected using floqSwabs from Copan Flock Technologies 
(Ref.#502CS01) and were immediately transferred to 2 ml preservative transport medium 
(DMEM; 01-055-1A, Beit Haemek and 1:1000 of Pen/Strep, 03-031-5C, Penicillin: 100,000 
units/ml, Streptomycin: 100 mg/ml, Beit Haemek). The samples were transported to the 
laboratory using a cool box. At the Virology Research Laboratory (VRL), the collection tubes 
containing the NPA swab were mixed vigorously under the biological hood, swabs were 
discarded and the medium was aliquoted, and finally stored at -20 °C. 
 
 
2.3  RNA Extraction of Influenza A Virus  
Influenza A RNA was extracted from the nasopharyngeal aspirate using the QIAamp Viral RNA 
Mini kit (Cat. # 52906, Qiagen, Hilden, Germany). The extraction steps were performed 
according to the manufacturer's instruction with slight modifications as follows: 
1. 140 μl nasopharyngeal aspirate were pipetted into a 1.5 ml microcentrifuge tube 
2. 560 μl AVL buffer containing RNA carrier (554.4 μl AVL buffer and 5.6 μl RNA carrier) 
were added to the sample and mixed. 
3. The mixture was incubated at room temperature for 10 min. 
4. 650 µl ethanol (96-100 %) were added to the sample, mixed by vortexing for 15 sec and 
briefly centrifuged to remove drops from the inside of the tube lid.  
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5. 630 µl of the solution from the previous step were transferred carefully to the QIAamp 
Mini spin column (in a 2ml collection tube) without wetting the rim.  The cap was closed 
and the column in the collection tube was centrifuged at 8000 rpm using a Hettich 
centrifuge (Hettich, Germany) for 1 min.  
6.  The QIAamp Mini spin column was placed in a clean 2ml collection tube, and the tube 
containing the filtrate was discarded.   
7. Steps 5 and 6 were repeated. 
8. 500 μl Buffer AW1 were added to the QIAamp Mini spin column without wetting the rim 
and centrifuged at 8000 rpm for 1 min.  The filtrate was discarded and a QIAamp Mini 
spin column was placed in a clean 2 ml collection tube. 
9. 500 μl Buffer AW2 were added and centrifuged at 14000 rpm for 3 min.  
10. Filtrate was discarded and centrifugation was repeated for 1 min to ensure flow-through 
of the entire amount of Buffer AW2. 
11.  Finally, the QIAamp Mini spin column was placed in a clean microcentrifuge tube, 80 μl 
AVE buffer was added to the column, incubated at room temperature for 1 min and 
centrifuged at 8000 rpm for 1 min.  The filtrate in this step contained the extracted RNA, 
which was stored at -20 °C.  
 
 
2.4  Amplification of the HA and NA Genes of Influenza A 
Amplification of the HA and NA genes occurred in a one step RT-PCR reaction using One-Step 
RT-PCR Kit (Cat# 210212, Qiagen, Hilden, Germany). Complete HA and NA genes were 
amplified using either WHO recommended primers or a modified variation of those primer sets 
as summarized in Table 2.1. Two of these primers were modified during this research to enhance 
the yield of the RT-PCR product, “m” was added to the original name of these modified primer, 
as illuminated in Table 2.1. A H1N1 sample isolated in 2013 at the Virology Research 
Laboratory was used as a positive control and included in this study.   
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Table 2.1: Primer sets used to amplify the HA and NA genes of H1N1 and H3N2 influenza 
A subtypes. The primers were obtained from WHO recommendation protocol for the detection 
of H1N1 and H3N2; “m” was added to each primer modified for this research. From: 
(http://www.who.int/influenza/resources/documents/molecular_diagnosis_influenza_virus_huma
ns_update_201108.pdf). 
   
Type/subtype Gene 
Fragment 
Primer Sequence PCR 
Product 
(bp) 
Influenza 
A(H1N1)2009 
HA-5’(H1) H1F1  
H1R1 
AGCAAAAGCAGGGGAAAATAAAAGC 
CCTACTGCTGTGAACTGTGTATTC 
1264 
 
 HA-3’(H1) H1F2 
H1R2 
GCAATGGAAAGAAATGCTGGATCTG 
ATATCGTCTCGTATTAGTAGAAACAAGGGT
GTTTT 
945 
 
 NA-5’(N1) N1F1 
N1R1 
GCAAAAGCAGGAGTTTAAAATG 
CCTATCCAAACACCATTGCCGTAT 
1099 
 
 NA-3’(N1) N1F2 
N1R2 
GGAATGCAGAACCTTCTTCTTGAC 
ATATGGTCTCGTATTAGTAGAAACAAGGAG
TTTTTT 
1073 
Influenza 
A(H3N2) 
HA-5’(H3) H3F1 
H3R1 
AAGCAGGGGATAATTCTATTAACC 
GTCTATCATTCCCTCCCAACCATT 
1127 
 HA-3’(H3) H3F2 
H3R2 
TGCATCACTCCAAATGGAAGCATT 
ATATCGTCTCGTATTAGTAGAAACAAGGGT
GTTTT 
863 
 NA-5’(N2) N2F1 
N2R1 
N2R1m 
 
TATTGGTCTCAGGGAGCAAAAGCAGGAGT 
ATCCACACGTCATTTCCATCGTCA 
ATCCACACGTCATTTCCATCATCA 
1118 
 NA-3’(N2) N2F2 
N2F2m 
N2R2 
AAACTAGYAGAATACAGRAATTGGTC 
AAACCAGCAGAATACAGAAATTGGTC 
ATATGGTCTCGTATTAGTAGAAACAAGGAG
TTTTTT 
1226 
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Initially, the presence of IAV was tested by amplifying a region of the M gene, which is highly 
conserved in all Influenza A types, using the following forward and reverse primers M52C (5′-
CTT CTA ACC GAG GTC GAA ACG-3′) and M253R (5′-AGG GCA TTT TGG ACA AAG/T 
CGT CTA-3′) (Fouchier et al, 2000). Unfortunately, this primer pair amplified an additional non-
specific PCR product. Therefore, screening for IAV was performed according to the WHO 
recommendations using one set of H1 and one set of H3 primers indicated in Table 2.1. Positive 
samples with visible yield of PCR product were then subjected to analysis of the whole HA and 
NA genes using the rest of the primer sets  (Table 2.1). 
 
 
2.5   Condition of the RT-PCR Reaction 
A total RT-PCR reaction of 20 μl included 12.8 μl extracted RNA, 0.8 μl of each primer (each 10 
pmol/μl), 0.8 μl of dNTP mix, 0.8 μl of QIAGEN OneStep RT-PCR Enzyme Mix (cat#210212) 
and 4 μl of QIAGEN One-Step RT-PCR Buffer (5x). The reaction was carried out in a special 
PCR tube (0.2 ml Axygen Inc., USA) using Swift™ MaxPro Thermal Cyclers (ESCO Global, 
USA).  The RT-PCR reaction started with a single reverse transcription step for 30 min at 50ºC 
followed by a single denaturation step for 15 min at 95ºC to activate HotStart Taq DNA 
polymerase and inactivates the reverse transcriptase. Amplification was achieved in 40 cycles 
using two different annealing temperature as followed; 20 cycles of 1 min at 95ºC for 
denaturation, 1 min at 55 ºC for annealing and 2 min at 72 ºC for extension respectively, 
followed by another 20 cycles of the same order, using 60 ºC for annealing. An additional 
extension step was performed for a further 10 min at 72 ºC, to assure a complete extension of the 
amplified product.  The reaction was then cooled down to 4ºC and either stored at -20 ºC or used 
directly for analysis. 
 
 
2.6  Detection of the RT-PCR Product 
To detect the amplified gene product of the RT-PCR reactions, agarose gel electrophoresis was 
used to separate the amplified product of expected size. 1 % agarose (Amresco) gel was prepared 
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in 1x TAE (10 x TAE = 400nM Tris-HCL, pH 8.3; 200mM Na-Acetate; 20 mM EDTA).  The 
agarose was boiled until it was well dissolved; ethidium bromide was added when agarose 
suspension had cooled down to 45ºC, carefully mixed, poured into the agarose gel casting system 
(BioRad, UK or Cleaver, U.S.A) and a comb for the generation of sample slots was inserted.      
4 μl of the 6x DNA loading dye Cat. No #R0611 (Thermoscientific) were added to the 20 μl RT-
PCR product and then 22 μl of this mixture were filled into one gel slot along with the DNA size 
control; 2 µl from 100 bp marker (gene ruler express DNA ladder, Fermentas, Cat. # SM1558). 
After running the electrophoresis (100 mv for 30min) using a Bio Rad power supply, the 
migrated DNA bands in the agarose gel were visualized under UV light.  A digital image of the 
gel was taken using a gel documentation system (MicroBis gel documentation system, DNR Bio-
Imaging Systems Ltd.). 
 
 
2.7  Gel Purification of RT-PCR Product 
The desired RT-PCR product visualized on agarose gel was excised with a clean, sharp scalpel 
and placed in a clean 1.5 ml microcentrifuge tube. The DNA was extracted from the gel using 
MinElute Gel Extraction Kit (Cat.# 28704, Qiagen, Hilden, Germany). The steps were performed 
according to the manufacturer's instruction as follows: 
1. The gel slice was weighed in the microcentrifuge tube and 3 volumes of Buffer QG were 
added to 1 volume of gel. 
2. The mixture was incubated at 50°C for 10 min (or until the gel slice has completely 
dissolved). To help dissolve the gel, tube was mixed by vortexing every 2–3 min during 
the incubation period. 
3. After the gel slice has dissolved completely, the color of the mixture turns yellow (similar 
to Buffer QG without dissolved agarose).  
4. 1 gel volume of isopropanol was added to the tube and mixed 
5. The mixture was applied to the QIAquick column (maximum volume is 800 μl) in a 
provided 2 ml collection tube, and centrifuged at 8000 rpm for 1 min. 
6. The flow-through was discarded and QIAquick column was placed back in the same 
collection tube. 
7. Steps 5 and 6 were repeated. 
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8. 500 μl of Buffer QG were added to QIAquick column and centrifuged at 8000 rpm for 1 
min. 
9. 750 μl of Buffer PE were added to QIAquick column, let stand 2–5 min and centrifuged 
for 1 min. 
10. The flow-through was discarded and the column was centrifuged for an additional 1 min 
at 13,000 rpm. 
11. The QIAquick column was placed into a clean 1.5 ml microcentrifuge tube, and 10 μl of 
elution buffer EB (10 mM Tris·Cl, pH 8.5) were added carefully to the center of the 
QIAquick membrane, incubated for 1 min and centrifuged for 1 min at maximum speed. 
The filtrate in this step contained the purified DNA of the PCR product and was used for 
sequencing. 
 
 
2.8  HA and NA Sequencing 
10% of the purified RT-PCR obtained in step 2.7 was subjected to gel electrophoresis analysis 
(see 2.6 for details) to confirm the presence of sufficient amount of the PCR product. If the 
purified PCR product was visible at this step, it was subjected to sequencing (ABI 3730xl DNA 
Analyzer, Hy-labs Ltd., via by BioTech Medical Supplies Co, Ltd, Ramallah).  
  
 
2.9 HA and NA Sequence Analysis 
Every PCR product representing the HA and the NA gene was subjected to forward and reverse 
sequence analysis.  Sequences were subjected to different bioinformatics analyses. 
 
 
2.9.1 Quality and Identification of Sequences  
To determine the quality of the sequences received, an initial check took place using the 
Chromas program Version 2.4.4, Technelysium Ltd (www.technelysium.com.au/chromas.html). 
If the nucleotide peaks were sharp and clear, sequence was subjected to NCBI blast 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). This search machinery releases the most recent NCBI 
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archived sequences, including accession numbers, matching the blasted one. These matching 
archived sequences were saved and used in the next step, where the exact sequence analysis took 
place using the Lasergene program, version 12 (DNASTARInc., Madison, WI, USA). This basic 
search is essential, as it identifies whether the obtained sequence is an influenza A on first place 
or not and of which subtype. This search is critical, especially in the beginning of this research, 
when encountered the amplification of an additional non-specific product using one of the eight 
primer pairs. Other than that, all RT-PCR products were identified as IAV specific subtypes for 
H1, N1, H3, and N2. 
 
 
2.9.2  Sequence Analysis using MegAlign of DNAStar Program 
Although the received sequences were subjected to an overview sequence analysis using the 
NCBI blast machinery and had proven to be the influenza subtypes H1N1 or H3N2, each single 
nucleotide was further verified using MegAlign of the Lasergene gene analysis program, version 
13 (DNASTARInc., Madison, WI, USA) by eye inspection of the sequence chromatogram. 
Hereby, each of H1, N1, H3, and N2 sequences was analyzed separately.  
In the MegAlign program, each of the forward and the complementary strand of the reverse 
sequences were aligned with the matching NCBI archived sequences identified in 2.9.1 (see 
2.9.3). The program shows nucleotide differences in red.  Each of these red colored nucleotide 
was double checked in the Chromas chromatogram.  If the peak of the nucleotide colored red in 
MegAlign was a sharp and clear peak in Chromas chromatogram, no corrections were made and 
the red colored nucleotide was identified as a real substitution or mutation. If the nucleotide 
colored red in MegAlign was not the result of a clear peak in Chromas chromatogram, but was a 
result of error in readout, the red colored nucleotide was replaced by the nucleotide with eye 
inspected clear peak at that exact position.  
 
 
2.9.3   Influenza A virus Reference Sequences  
In order to identify the IAV sequences revealed from Palestinian samples, NCBI archived 
(identified in step 2.9.1) complete Human influenza A virus H1N1 and H3N2 for both HA and 
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NA genes sequences were used as references. If the archived sequences identified in 2.9.1 were 
not representing a wide range of that subtype, further matching was looked up among the same 
subtype. NCBI archives sequences were referred to by the HA (hemagglutinin) subtype;  H1 or 
H3, or the NA (neuraminidase) subtype; N1 or N2 along with its NCBI accession number, the 
country, and year of isolation.    
The following reference sequences were used for H1: 251748192 (A/Hong 
Kong/2369/2009(H1N1)), 937144530 (A/California/80/2015(H1N1)), 937144979 
(A/Hawaii/01/2015(H1N1)), 937144870 (A/Washington/19/2015(H1N1)), 344166270 
(A/Amman/WARAIR3448T/2010(H1N1)), 432339562 (A/Ankara/02/2011(H1N1)), 319979564 
(A/Tunisia/422/2011(H1N1)), 432339455 (A/Jeddah/3670/2010(H1N1)), 798777532 
(A/Thailand/CU1282/2014(H1N1)), 937144654 (A/Alaska/36/2014(H1N1)), 695309506(A/ 
Finland/61/2014(H1N1)), 756762858 (A/Egypt/42/2014(H1N1)), 670605152 (A/Oman/SQUH-
76/2013(H1N1)), 530311445 (A/Kenya/268/2013(H1N1)), 831432909 
(A/Mexico/200039/2014(H1N1)), 649965521 (A/Japan/3746/2014(H1N1)), 880801824 
(A/Singapore/DMS1316/2013(H1N1)), 984687764 (A/Florida/92/2014(H1N1)), 906489051 
(A/Indore/3598/2015(H1N1)), 229783366 (A/Korea/01/2009(H1N1)), 283580622 
(A/Novosibirsk/02/2009(H1N1)), 582048552 (A/Israel/4960/ 2013(H1N1)) (partial gene), 
253828584 A/California/19/2009(H1N1) and the vaccine strain 474459624  
(A/California/7/2009(H1N1)).  
The following reference sequences were used for N1: 251748197 (A/Hong 
Kong/2369/2009(H1N1)), 937144549 (A/California/80/2015(H1N1)), 344166274 
(A/Amman/WRAIR3448T/2010(H1N1)), 432339437 (A/Jeddah/3670/2010(H1N1)), 670605234 
(A/Oman/SQUH-76/2013(H1N1)), 756762862  (A/Egypt/42/2014(H1N1)), 937144041 
(A/Hawaii/01/2015(H1N1)), 937144676 (A/Alaska/36/2014(H1N1)), 767169925 
(A/Nagasaki/13N075/2014(H1N1)), 937144748 (A/Washington/19/2015(H1N1)), 669251020 
(A/Helsinki/473N/2014(H1N1)), 984687768 (A/Florida/92/2015(H1N1)), 831432913 
(A/Mexico/200039/2014(H1N1)), 880801828 (A/Singapore/DMS1316/2013(H1N1)), 
973426644 (A/Assam/536/2015/(H1N1)), 957742747 (A/Thailand/CUF52/2014(H1N1)), 
530311431 (A/Kenya/262/2013(H1N1)), 698322614 (A/Shanghai/6109/2014(H1N1)),  
596531120 (A/Melbourne/IN53_670/2011(H1N1)), 237689849 (A/Israel/644/2009(H1N1))  and 
the vaccine strain 474459622 (A/California/7/2009(H1N1)).  
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The following reference sequences were used for H3: 937163288 
(A/California/80/2015(H3N2)), 937161830 (A/Hawaii/12/ 2015(H3N2)), 984694250 
(A/Florida/82/2015(H3N2)), 937167679 (A/Alaska/150/2015(H3N2)), 937163291 
(A/Washington/34/2015(H3N2)), 950734496 (A/South Korea/4784/2015(H3N2)), 666878653 
(A/Singapore/H2013.181/2013(H3N2)), 950734760 (A/Japan/4810/2015(H3N2)), 530311486 
(A/Kenya/254/2013(H3N2)), 383446947 (A/Novosibirsk/R1108/2012(H3N2)), 824038237 
(A/Czech Republic/93/2015(H3N2)), 672590107 (A/Guangdong/1154/2012(H3N2)), 506460432 
(A/Tunisia/1987/2013(H3N2)), 469933976 (A/Riyadh/01/2010(H3N2)), 559147575 
(A/Helsinki/716/2013(H3N2)), 938454111 (A/Dubai/NHRC_CVS0031/2014(H3N2)), 
585478743 (A/Tehran/44476/2013(H3N2)), 779786654 (A/Bangkok/151-MI21/2015(H3N2)), 
937163351  (A/Ohio/11/2015(H3N2)), 568261144 (A/Delhi/2487/2013(H3N2)), 844289318 
(A/Israel/P-687/2015(H3N2)) (partial), and  the vaccine strain 488466327 
(A/Texas/50/2012(H3N2)).  
The following reference sequences were used for N2: 341610522 (A/Hong Kong/H090-783-
V1(0)/2009(H3N2)), 585478782 (A/Tehran/44476/2013(H3N2)), 469933978 
(A/Riyadh/01/2010(H3N2)), 559147570 (A/Helsinki/716/2013(H3N2)), 937161836 
(A/Hawaii/12/2015(H3N2)), 984694254 (A/Florida/82/2015(H3N2)), 937167684 
(A/Alaska/150/2015(H3N2)), 937163177 (A/Washington/34/2015(H3N2)), 666879366 
(A/Singapore/H2013181/2013(H3N2)), 530311510 (A/Kenya/254/2013(H3N2)), 383 446 951 
(A/Novosibirsk/RII08/2012(H3N2)), 844289328 (A/Beijing/6066/2014(H3N2)), 767170015 
(A/Nagasaki/13N020/2014(H3N2)), 779786910 (A/Bangkok/SI-MI21/2015(H3N2)), 937163470 
(A/New Jersey/16/2015(H3N2)), 937158535 (A/Oklahoma/01/2015(H3N2)), 973164450 
(A/Ohio/11/2015(H3N2)), 568261255 (A/Delhi/2487/2013(H3N2)), 938454119 
(A/Dubai/NHRC_CV0031/2014(H3N2)) (partial), and the vaccine strain 488466301 
(A/Texas/50/2012(H3N2)). 
 
2.9.4 Sequence Alignment Criteria in MegAlign 
All alignments were made using the Clustal W method of the MegAlign program with the 
following alignment conditions: Pairwise alignment was always slow accurate with gap penalty 
10, gap length 0.10, protein weight matrix Gonnet 250 and DNA weight matrix IUB.  The same 
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parameters were used for the multiple alignments except for the gap length, which was 0.20. 
These were the default parameters suggested by the program to fulfill the most ideal sequence 
alignment.  The Clustal W method aligns sequences using the method of Thompson et al. (1994).  
Clustal W method was designed to create more accurate alignments than Clustal V when 
alignments include highly divergent sequences.  Gap penalty is the amount deduced from the 
alignment score for each gap in the alignment. 
 
 
2.9.5  Merging Sequences of the Same Gene; Gene Assembly from Partial Sequences 
Sequence fragments representing the same gene were merged together to produce the whole or 
the longest partial gene possible of each of the HA and NA segments. Merging sequence 
fragments were performed using SeqMan Pro of the Lasergene gene analysis program, version 
13 (DNASTARInc., Madison, WI, USA). The classic assembler was chosen as the assemble 
method with the following default assembling parameters: match size 12, minimum match 
percentage 80, minimum sequence length 100, 70 for the maximum added gaps per kb in both 
the contig and in sequence, gap penalty 0.00 and gap length 0.70. After assembly the merged 
sequence was used for the final sequence analysis in MegAlign (DNASTARInc., Madison, WI, 
USA). 
 
 
2.9.6  Analysis of Nucleotide and Amino Acid Substitutions and Mutations in the  
          Palestinian IAV Isolates 
For accurate mutation analysis of Palestinian IAV samples, samples aligned with reference genes 
in MegAlign DNASTAR program were eye inspected. The program colors the nucleotides 
differences in the DNA mode precisely in red and can therefore be easily tracked (Figure 2.1).  
Once a nucleotide substitution was detected, amino acid (AA) mode was checked to test whether 
the nucleotide substitution resulted in AA exchange (Figure 2.2). An example of non-
synonymous substitution is the nucleotide substitution G to A (region is marked in Figure 2.1), 
which changed the genetic code from GCT to ACT and caused the AA exchange A (Alanine) to 
T (Threonine) (region is marked in Figure 2.2). An example of synonymous substitution (Figure 
2.1, green arrow) shows the exchange of the genetic code TCT to TCC, both encoding Serine. 
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Figure 2.1:  DNA nucleotide MegAlign example of H3 gene of Palestinian IAV isolates.  
Palestinian isolates (marked blue) are aligned with reference sequences for H3 gene (marked 
red).  Non-synonymous substitution is pointed to with red arrow (G682A, which causes the AA 
exchange A228T, see Figure 2.2).  An example of synonymous substitution is pointed to with 
green arrow. 
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Figure 2.2: Amino acid MegAlign example of H3 gene of Palestinian IAV isolates.  
Palestinian samples (marked bright blue) are aligned with reference sequences for H3 gene 
(marked red).  AA exchanges are pointed to with red arrows.  The AA exchange example given 
here is A228T. 
 
 
2.9.7  Characterizing Identified Nucleotide and AA Substitutions 
PubMed search machinery was used to look for nucleotide and AA substitutions identified in the 
Palestinian isolates to find out whether they are functionally essential or not, true mutations or 
not, etc. Once a publication had been identified to characterize the mutation, the publication was 
marked as a reference. If the substitution was not found in literature, nor in the NCBI-archive 
reference sequences, it was referred to as novel. In case of the NA gene region, the influence of 
the mutation on drug susceptibility was the main concern. Beside MegAlign results and 
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phylogenetic analysis, sequences were inserted into NCBI Influenza Virus Resource 
(https://www.ncbi.nlm.nih.gov/genome/viruses/variation/flu/), where drug resistance encoding 
regions can be identified. 
 
 
2.9.8  Phylogenetic Analysis 
MegAlign pro program (DNASTAR) was used to generate the phylogenetic trees analyzing 
relevance of the different sequences to each other.  MegAlign pro uses the biological neighbor 
joining method, which depends on evolutionary distances obtained from aligned sequences 
(Cascuel, 1997).  To generate the trees, the sequences were aligned using default parameters of 
Clustal Omega method.  The values for sequence percent identity were obtained using the 
sequence distance feature in the MegAlign program (DNASTAR). 
 
 
2.10  Statistical Analysis 
Statistical analysis was performed using the statistical program R (R Core Team, 2016). Chi-
square test was used to test the association between two categorical variables for significance. 
Contingency table was used to summarize the frequency distributions of the variables. 
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3. Results  
3.1  Data of Study Population 
3.1.1    Sample Size and Collection Time 
200 NPA samples were collected between February 10th and May 5th. While 19 (9.5%) of the 
samples were collected in February, most of them were collected in March (96=48%) and April 
(67=33.5%). Finally, 18 (=9%) of the 200 samples were collected in May. 
 
 
3.1.2    Study Sample  
Most of the NPA samples were collected from kindergarten children (48%), but nearly equal 
numbers of samples were collected from hospitalized patients (17.5%), medical private clinic 
patients (17%) and privately (17.5%). As for sex of the study sample, 58.5% were males, while 
41.5% were females. 
The age groups were basically divided according to high-risk population for infection with IAV 
(CDC, Flu Website, 2016). Further factors critical to genetic epidemiology studies were 
considered for age group categorization in this study. Such factors are: all infants (group ≤ 1 
year) were either visiting a private clinic or hospitalized, most children before school age (group 
> 1-6 years) were attending kindergartens, and that all participants between 7-18 years were 
attending schools (group 7-18 years). There were only five participants belonging to risk group 
aged >64 years and they were therefore categorized within the group > 18 years. The distribution 
of participants and their percentage within the age groups and collection sites is summarized in 
Table 3.1. The largest age group was the > 1-6 group with 126 participants, most of which were 
collected from kindergartens.  
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Table 3.1: Distribution of age group among the different collection sites. Study population 
was divided into four age groups, distributed within the four collection sites. 
Age groups Total Number 
(%) 
Hospitalized 
patients 
Medical clinic 
patients 
Kindergarten 
children 
Private 
( ≤ 1 year) 23 (11.5) 30.4% 65.5% 0% 13.1% 
( > 1-6 years) 126 (63) 0.8% 15.9% 76.2% 7.1% 
(7-18 years) 10 (5) 0% 10% 0% 90% 
(> 18 years) 41 (20.5) 65.9% 0% 0% 34.1% 
 
 
3.1.3    Residency  
The majority of participants were from Jerusalem (75.5%), some were from Ramallah and 
northern Palestine (Nablus and Tulkarem) (19%) and few were from southern Palestine; Hebron 
and Bethlehem (5.5%). A single participant from Jaffa was included within the Jerusalem 
sample. Finally, two participants from Jericho were included within the Ramallah and northern 
Palestine sample. 
 
 
3.1.4    Travel Outside Palestine and Residency Near Poultry Farms 
Since traveling abroad might be a risk for acquiring respiratory tract infections, our consent form 
included a question regarding “visit abroad”, if and when. 170 of the 200 participants(85%) 
reacted to this question, 11 of the 170 answered yes. While nine were abroad either more than 2 
weeks before sampling or did not indicate their travel date, two were abroad only few days prior 
sampling for our study. One of these participants was in Jordan, while the other was in Saudi 
Arabia doing “Umrah”.  
Another risk factor for acquiring influenza specifically could be residency around poultry farms 
or raising poultry privately in the backyard. 166 of the 200 participants (83%) reacted to this 
question; 32 of the 166 answered yes.  
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3.2  Participants’ Medical Records 
3.2.1    Clinical Observation 
The most common symptom among the 200 participants was runny nose (76.5%), followed by 
cough (42.2%) and fever (21.4%). 3.5% of the participants suffered from shortness of breath and 
3% were discharging sputum. Single cases (three) indicated to have sore throat, diarrhea, vomit, 
and chest pain. All cases presented with shortness of breath, diarrhea, or chest pain were 
hospitalized. 
Clinical diagnostic was indicated in 16 cases (16 out of the 200); all 16 cases were either 
hospitalized or visiting medical clinics, therefore diagnostic was provided by the physician.  Of 
the 16 cases, 6 (37.5%) were diagnosed with ear infection, 4 (25%) presented with bronchitis, 3 
(18.8%) with chest infection, 2 (12.5%) with typical flu, and 1 (6.2%) with upper respiratory 
tract infections. 
  
 
3.2.2    Drug Administration and Vaccination 
83 (41.5%) of the 200 participants reacted the question regarding drug administration, 26 of the 
83 answered yes. Six of the 26 received a combination of two types of antibiotics; two received 
one type of antibiotic in combination with oseltamivir. Antibiotics were administrated in 92.3% 
of these 26 cases, oseltamivir (Tamiflu) in 23% (all hospitalized), and salbutamol (Ventolin) in 
3.8%. The major antibiotic administrated in the 26 cases was cefetriaxone (40.9%), 
amoxicillin/clavulanic acid (18.2%), and vancomycin (13.6%). Single cases received other 
antibiotics such as ofloxacillin, ampicillin, cefotaxime, imepenem, meropenem, moxyflxacin, 
levofloxacin, and azithromycin.  
141 of the 200 participants answered the question about vaccination with influenza vaccine. Only 
15 of these 141 received Influenza vaccine for the season 2014-2015. 11 of the 15 cases belong 
to the age group >1-6 years, and 4 to the age group >18 years. 
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3.3  Influenza A Virus Positive Population 
50 samples (25%) of the collected 200 NPA tested positive for influenza A virus (IAV). 24 
(48%) of the IAV positive cases were infected with H1N1 subtype, and 26 (52%) were infected 
with H3N2 subtype.  All of the percentages presented in the following results were calculated 
relative to this total of 50 positive samples. As the number of samples for each variable, month, 
residency, collection site, etc., was not equal, IAV samples were calculated relative to the total 
number of samples in that exact category to avoid bias in significance. 
 
 
3.3.1    Monthly Distribution  
Monthly distribution of IAV positive samples was calculated relative to the total number of 
samples collected each month (see 3.1.1). For example, 19 samples were collected in February, 
five of which tested positive for IAV; this means that 26.3% of the samples collected in February 
were positive for IAV. Interestingly, the percentage of IAV positive samples relative to the total 
samples collected each month (see 3.1.1) is almost equal among the months as follows: 26.3% on 
February, 21.8% on March, 29.9% on April and 22.2% on May (Figure 3.1).  
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Figure 3.1: Distribution of IAV in the months of collection. The percentages were calculated 
out of the number of 50 IAV positive samples for each month relative to the total number of 
samples collected in that month.  
 
 
The monthly distribution of the H1N1 and H3N2 subtypes was variable; the majority of the 24 
H1N1 cases were detected in April, while the majority of the 26 H3N2 cases were detected in 
March (Figure 3.2). The calculation in Figure 3.2 was made relative to the 50 IAV positive 
samples.  For examples, in February, five samples were IAV positive, one (=2% of the 50 IAV 
samples) was H1N1 and 4 (=8% of the 50 IAV samples) were H3N2. 
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Figure 3.2: Distribution of IAV subtypes in the months of collection. 48% of the 50 IAV 
samples were H1N1, 2% were isolated in February, 6% in March, 38% in April, and 2% in May. 
52% of the 50 IAV samples were H3N2, 8% were isolated in February, 36% in March, 2% in 
April, and 6% in May, respectively.  
 
 
3.3.2    Age and Sex  
The percentages of cases infected with IAV throughout the four age groups relative to the 
number of total samples presented in each group (see Table 3.1) were 30.4%, 23.8%, 20%, and 
26.8% for age group ≤ 1 year, > 1-6 years, 7-18 years, and > 18 years, respectively (Figure 3.3). 
The distribution of IAV subtypes throughout the different age groups is illuminated in Figure 
3.4. Most of the IAV infections in the eldest age group were due to H1N1. Infections with H1N1 
and H3N2 were almost equal in the age groups > 1-6 years and 7-18 years, while most of the 
IAV infections in the youngest age group; ≤ 1 year, were caused by H3N2 subtype.  
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IAV infection distributed almost equally between males (54%) and females (46 %), however, 
subtype H3N2 was responsible for most IAV infections among males (65.4%) and H1N1 caused 
more infections in females (58.3%). 
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Figure 3.3: Distribution of IAV in the different age groups. The distribution of IAV positive 
cases throughout the different age groups was calculated relative to the total of participants of the 
same age group. 
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Figure 3.4: Distribution of H1N1 and H3N2 subtypes in the different age groups. 48% of the 
50 IAV samples were H1N1, 4% were isolated from the youngest age group, 24% in the >1-6 
years, 2% in the 7-18 years, and 18% in the eldest age group. 52% of the 50 IAV samples were 
H3N2, 10% were isolated from the youngest age group, 36% in the >1-6 years, 2% in the 7-18 
years, and 4% in the eldest age group, respectively. 
 
 
3.3.3    Residency and Collection Site Distribution of IAV Cases 
24.5% of samples collected from Jerusalem tested positive for IAV, 26.3%, and 27.3% of those 
samples collected from Ramallah/Northern Palestine and Southern Palestine tested positive for 
IAV (Figure 3.5).  Interestingly, H1N1 and H3N2 infections distributed almost equally 
throughout these sampling areas (Figure 3.6). 
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Figure 3.5: The distribution of IAV positive samples in collection districts. The percentages 
were calculated relative to the total of samples collected in each district:  37 samples tested 
positive for IAV from the151 samples collected from Jerusalem (24.5%), 10 samples tested 
positive for IAV from the 38 samples collected from Ramallah/Northern Palestine (26.3%) and 3 
samples tested positive for IAV from the11 samples collected from Southern Palestine (27.3%) 
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Figure 3.6: The distribution of H1N1 and H3N2 subtypes in collection districts. The 
percentages of subtypes were calculated relative to the total of the positive IAV samples (n=50). 
 
IAV positive samples distributed almost equally among the different collection sites as indicated 
in Figure 3.7).  In regard to the subtypes, H3N2 subtype was responsible for most infections in 
Kindergartens group, while H1N1 caused most infections in the privately collected group (Figure 
3.8).  Both subtypes distributed almost equally in the medical clinic and Hospital groups.  
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Figure 3.7: The distribution of IAV positive cases in the different collection sites. The 
percentages were calculated relative to the total of samples collected in each collection site: 22 
IAV positive cases out of 96 samples collected from kindergartens (22.9%),  9 IAV positive 
cases out of 35 samples collected privately (25.7%), 9 IAV positive cases out of 35 samples 
collected from hospitals(25.7%), 10 IAV positive cases out of 34 samples collected from medical 
clinic (29.4%). 
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Figure 3.8: The distribution of H1N1 and H3N2 subtypes in collection sites. 48% of the 50 
IAV samples were H1N1, 28% were isolated from Kindergartens, 6% from private, 8% from 
hospitals, and 10% from medical clinics. 52% of the 50 IAV samples were H3N2, 16% were 
isolated from Kindergartens, 12% from private, 10% from hospitals, and 10% from medical 
clinics, respectively. 
 
  
 
3.3.4    IAV Distribution relative to Travel Outside Palestine and Residency near Poultry  
            Farms            
IAV was positive in two participants, who were abroad before sampling; both were infected with 
H1N1 subtype. Interestingly one of these was in “Umrah”. 
Among those 166 participants, who indicated to live around poultry farms, 18.8% were infected 
with IAV, while 21.6% of those, who answered with no were infected with IAV. H3N2 was 
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responsible for most IAV infections in those who lived around poultry farms or private raised 
poultry; the rate was equal between H3N2 and H1N1 in those who answered no (Figure 3.9). 
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Figure 3.9: Distribution of IAV subtypes relative to residency near poultry farms. The 
percentage for each subtype and each group was calculated relative to the total number of 
positive IAV cases in each group.  
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3.3.5    Clinical Symptoms and Medical Diagnosis Among IAV Cases 
84.7% of IAV 50 infected cases suffered from runny nose, 45.6% suffered from cough and 
28.3% had fever.  Only single cases suffered from diarrhea, shortness of breath, or sputum 
discharge.  As for the IAV subtypes, the H3N2 positive cases suffered from runny nose (88%), 
cough (44%) and fever (30.8%). Similarly, 80.9%, 47.6%, and 23.8% of H1N1 cases presented 
with runny nose, cough, and fever, respectively. In addition the single cases suffered from 
diarrhea, shortness of breath, or sputum discharge were all infected with H1N1. 
Only three cases infected with IAV had diagnosis checked on the consent form and all were due 
to infection with subtype H3N2. One case was diagnosed with ear infection, another was 
diagnosed with bronchitis, and the third was indeed diagnosed as having a “typical Flu”. 
 
 
3.3.6    Drug Administration and Vaccination in IAV Cases 
Antibiotics and Tamiflu was administrated in 26 cases, all were hospitalized or visiting medical 
clinics, 6 cases of these (23%) tested positive for IAV, however, none of these 6 cases received 
Tamiflu. The rate of IAV infections among those who did not receive medications was 21%. 
H1N1 and H3N2 infections distributed almost equally in both categories (those who received 
and those who did not receive medications).  
26.7% of those who received the seasonal Influenza A vaccine, and 18.9% of those who did not, 
tested positive for IAV.  H1N1 and H3N2 infection distributed almost equally in both categories.  
 
 
3.4 Efficiency and Specifity of the RT-PCR Reaction 
3.4.1 Efficiency and Specifity of the Primers   
Screening for the presence of IAV was initially performed using a primer pair specific for the M 
gene of IAV, later this step was skipped and replaced by direct amplification of the H and N 
genes. Hereby, primer pair N1F2/N1R2 was used to identify H1N1 subtype, and primer pair 
H3F2/H3R2 was used to identify H3N2.  Once tested positive, the sample was subjected to RT-
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PCR amplification using the rest of the primer pairs with the aim to amplify the entire H and N 
genes.  
 
 
3.4.2 Efficiency of the RT-PCR Reaction 
The RT-PCR reaction was optimized stepwise before using the final conditions illuminated in 
2.5. The melting temperature of the primers varied and ranged between 60 C and over 90 C, 
therefore different annealing temperature between 50 C and 65 C were tested. The experiments 
demonstrated that two cycles with two different annealing temperatures at 55 C and 60 C 
revealed the best RT-PCR harvest.  
 
 
3.4.3  Amplification of HA and NA genes  
Samples screened positive for either H1N1 or H3N2 using the screening primer pair were 
subjected to RT-PCR analysis using the rest of the primer pairs for each subtype in order to 
amplify the entire open reading frame of the HA and NA genes. Examples of the different RT-
PCR reactions using the different primer pairs are shown in Figure 3.10. Figure 3.10 illuminates 
that the RT-PCR harvest was not equally optimal for all samples tested and all primer pairs.  
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Figure 3.10: Amplification results of the RT-PCR reactions using the different primer pairs 
designated for HA and NA genes of H1N1 and H3N2 IAV subtypes. A) Amplification of 
HA-5’(H1) fragment (1264 bp) of the H1 gene using H1F1/H1R1 primer pair indicating the 
specific band in lanes 1, 6, and 7 and the non-specific band (~1000 bp) in lanes 2, 3, 4, 5, 8, and 
9. B) Amplification of HA-3’(H1) fragment (945 bp) of the H1 gene using H1F2/H1R2 primer 
pair in lanes 1 and 2, amplification of NA-5’(N1) fragment (1099 bp) of the N1 gene using 
N1F1/N1R1 primer pair in lanes 3 and 4, amplification of NA-3’(N1) fragment (1073 bp) of the 
N1 gene using N1F2/N1R2 primer pair in lanes 5 and 6. C) Amplification of HA-5’(H3) 
fragment (1127 bp) of the H3 gene using H3F1/H3R1 primer pair. D) Amplification of HA-
3’(H3) fragment (863 bp) of the H3 gene using H3F1/H3R2 primer pair. E) Amplification of 
NA-5’(N2) fragment (1118 bp) of the N2 gene using N2F1/N2R1 primer pair. F) Amplification 
of NA-3’(N2) fragment (1226 bp) of the N2 gene using N2F2/N2R2 primer pair. +C is positive 
control, -C is negative control and M is the marker lane. 
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3.5 Sequencing Results of the HA and NA Genes 
The sequences’ span of each of the Palestinian HA and NA genes is indicated in Tables 3.2 and 
3.3. Following sequence verification as indicated in steps 2.9.2-2.9.5, exact nucleotide location 
of the retrieved sequences of the Palestinian isolates was identified using the MegAlign program. 
The reference genes served as orientation to verify the position of the sequenced nucleotides (nt) 
and amino acids (AA), illuminated in Figures 2.1 and 2.2 respectively. For further clarification, 
Table 3.4 summarizes the percentages of the lengths of each H1, H3, N1, and N2 genes retrieved 
for each Palestinian isolate, relative to the length of the complete ORF (open reading frame), 
from start to stop codon.   
A total of 115 sequences were successfully retrieved from the RT-PCR reaction amplifications of 
the HA and NA genes of the H1N1 and H3N2 subtypes detected in this study. The 115 
sequences (forward and reverse) belong to 58 different fragments of HA and NA genes of 23 
samples; 11 H1N1 (Table 3.2), and 12 H3N2 samples (Table 3.3). Merged sequences produced 
24 complete ORF; 14 for HA genes (1701 nt) and 10 NA genes (1410 nt), 10 partial genes; 2 HA 
genes (812 and 1064 nt) covering 48-63 % of the ORF; and 8 NA genes (999-1087 nt) covering 
71-77 % of the ORF (Table 3.4). 
Sequences were submitted to the GenBank and will be available under KY075819-KY075852.  
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Table 3.2: Sequences’ span of the coding region of H1 and N1 genes of IAV H1N1 subtype 
retrieved from Palestinian isolates. Position of the nucleotides (nt) and amino acid (AA) was 
allocated using the MegAlign program. Each sample number refers to one participant, from 
whom the IAV was isolated.  
Sample 
No. 
H1 Gene N1 Gene 
 H1F1 
nt 
(AA) 
H1R1 
nt 
(AA) 
H1F2 
nt 
(AA) 
H1R2 
nt 
(AA) 
N1F1 
nt 
(AA) 
N1R1 
nt 
(AA) 
N1F2 
nt 
(AA) 
N1R2 
nt 
(AA) 
21 1-1065 
(1-355) 
149-1189 
(51-396) 
860-1701 
(288-566) 
819-1701 
(274-566) 
21-1-070 
(8-357) 
1-1047 
(1-349) 
412-1410 
138-469 
395-1410 
(133-469) 
46 1-671 
(1-223) 
541-1190 
(181-
397) 
859-1701 
(287-566) 
820-1701 
(274-566) 
42-971 
(15-330) 
1-1042 
(1-347) 
432-1410 
145-469 
398-1410 
(134-469) 
167 1-1001 
(1-333) 
159-1191 
(54-397) 
860-1701 
288-566 
834-1701 
(279-566) 
12-1036 
(5-352) 
1-1051 
(1-350) 
423-1410 
142-469 
394-1410 
(132-469) 
301 1-604 
(1-202) 
604-1199 
(202-
400) 
841-1701 
281-566 
------ 15-1080 
(6-360) 
1-1056 
(1-351) 
408-1410 
137-469 
379-1410 
(127-469) 
141 ------ ------ ------ ------ ------ ------ 410-1410 
(138-469) 
380-1410 
(128-469) 
145 ------ ------ ------ ------ ------ ------ 409-1410 
(137-469) 
379-1410 
(127-469) 
165 ------ ------ ------ ------ ------ ------ 410-1410 
(138-469) 
383-1410 
(129-469) 
166 ------ ------ ------ ------ ------ ------ 409-1410 
(137-469) 
464-1410 
(132-469) 
170 ------ ------ ------ ------ ------ ------ 412-1410 
(138-469) 
380-1410 
(128-469) 
172 ------ ------ ------ ------ 22-638 
(8-213) 
------ 468-1021 
(157-340) 
------ 
188 ------ ------ ------ ------ ------ ------ 410-1410 
(138-469) 
379-1410 
(248-469) 
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Table 3.3: Sequences’ span of the coding region of H3 and N2 genes of IAV H3N2 subtype 
retrieved from Palestinian isolates. Position of the nucleotides (nt) and amino acid (AA) was 
located using the MegAlign program. Each sample number refers to one participant, from whom 
the IAV was isolated.  
Sample 
No. 
H3 Gene N2 Gene 
 H3F1 
nt 
(AA) 
H3R1 
nt 
(AA) 
H3F2 
nt 
(AA) 
H3R2 
nt 
(AA) 
N2F1 
nt 
(AA) 
N2R1 
nt 
(AA) 
N2F2 
nt 
(AA) 
N2R2 
nt 
(AA) 
1 
 
6-1088 
(3-363) 
1-1057 
(1-353) 
928-1701 
(297-566) 
889-1701 
(297-566) 
1-1083 
(1-361) 
1-1046 
(1-349) 
268-1410 
(90-469) 
303-1410 
(102-469) 
4 6-1092 
(3-364) 
18-1062 
(7-354) 
926-1701 
(297-566) 
889-1701 
(297-566) 
----- ----- ----- ----- 
9 7-1034 
(3-345) 
61-1063 
(21-355) 
928-1701 
(297-566) 
889-1701 
(297-566) 
1-1078 
(1-360) 
1-1046 
(1-349) 
----- ----- 
29 6-1088 
(3-363) 
98-1062 
(34-354) 
928-1701 
(297-566) 
889-1701 
(297-566) 
1-1077 
(1-359) 
1-1046 
(1-349) 
272-1405 
(92-468) 
307-1410 
(103-469) 
38 6-1087 
(3-363) 
1-1060 
(1-354) 
928-1701 
(297-566) 
889-1701 
(297-566) 
1-1078 
(1-360) 
1-1046 
(1-349) 
266-1229 
(90-409) 
279-1410 
(94-469) 
60 2-576 
(2-192) 
333-1051 
(112-350) 
917-1701 
(297-566) 
889-1701 
(297-566) 
1-1078 
(1-360) 
1-1046 
(1-349) 
275-1372 
(93-457) 
544-1410 
(182-469) 
61 1-683 
(1-228) 
345-1051 
(116-350) 
916-1701 
(297-566) 
889-1701 
(297-566) 
1-1080 
(1-360) 
1-1046 
(1-349) 
264-1395 
(90-465) 
343-1410 
(115-469) 
74 6-1078 
(3-359) 
1-1057 
(1-353) 
927-1701 
(297-566) 
889-1701 
(297-566) 
1-1082 
(1-360) 
1-1046 
(1-349) 
276-1144 
(93-381) 
832-1410 
(278-469) 
89 9-527 
(4-176) 
523-1073 
(175-358) 
----- ----- ----- ----- ----- ----- 
93 7-1081 
(3-361) 
4-1060 
(2-353) 
926-1701 
(297-566) 
889-1701 
(297-566) 
----- ----- ----- ----- 
109 30-1086 
(11-
362) 
11-1043 
(5-347) 
926-1701 
(297-566) 
889-1701 
(297-566) 
----- ----- ----- ----- 
177 ------ ------ 927-1701 
(297-566) 
889-1701 
(297-566) 
----- ----- ----- ----- 
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Table 3.4: Length of the HA and NA gene fragments retrieved in the 23 Palestinian isolates. 
Thirty four different genes (H1, H3, N1 and N2) retrieved from the twenty three Palestinian 
isolates.  ORF (open reading frame) length of H1 and H3 is 1701 nt; of N1 and N2 is 1410 nt.  
Sample No. Subtype Gene type Gene length % ORF 
Sample 1 H3N2 H3 1701 nt (whole gene) 100% 
Sample 1 H3N2 N2 1410 nt (whole gene) 100% 
Sample 4 H3N2 H3 1695 nt (whole gene) 99.6% 
Sample 9 H3N2 H3 1694 nt (whole gene) 99.6% 
Sample 9 H3N2 N2 1078 nt (partial gene) 63% 
 Sample 21 H1N1 H1 1701 nt (whole gene) 100% 
Sample 21 H1N1 N1 1410 nt (whole gene) 100% 
Sample 29 H3N2 H3 1695 nt (whole gene) 99.6% 
Sample 29 H3N2 N2 1410 nt (whole gene) 100% 
Sample 38 H3N2 H3 1700 nt (whole gene) 100% 
Sample 38 H3N2 N2 1410 nt (whole gene) 100% 
Sample 46 H1N1 H1 1701 nt (whole gene) 100% 
Sample 46 H1N1 N1 1410 nt (whole gene) 100% 
Sample 60 H3N2 H3 1699 nt (whole gene) 100% 
Sample 60 H3N2 N2 1410 nt (whole gene) 100% 
Sample 61 H3N2 H3 1701 nt (whole gene) 100% 
Sample 61 H3N2 N2 1410 nt (whole gene) 100% 
Sample 74 H3N2 H3 1701 nt (whole gene) 100% 
Sample 74 H3N2 N2 1410 nt (whole gene) 100% 
Sample 89 H3N2 H3 1064 nt (partial gene) 63% 
Sample 93 H3N2 H3 1697 nt (whole gene) 100% 
Sample 109 H3N2 H3 1690 nt (whole gene) 99.3% 
Sample 141 H1N1 N1 1030 nt (partial gene) 73% 
Sample 145 H1N1 N1 1031 nt (partial gene) 73.1% 
Sample 165 H1N1 N1 1027 nt (partial gene) 72.8% 
Sample 166 H1N1 N1 1001 nt (partial gene) 71% 
Sample 167 H1N1 H1 1701 nt (whole gene) 100% 
Sample 167 H1N1 N1 1410 nt (whole gene) 100% 
Sample 170 H1N1 N1 1030 nt (partial gene) 73% 
Sample 172 H1N1 N1 999 nt (partial gene) 71% 
Sample 177 H3N2 H3 812 nt (partial gene) 48% 
Sample 188 H1N1 N1 1031 nt (partial gene) 73.1% 
Sample 301(2013) H1N1 H1 1701 nt (whole gene) 100% 
Sample 301(2013) H1N1 N1 1410 nt (whole gene) 100% 
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3.6 Nucleotide and Amino Acid Substitutions in the HA and NA Genes 
The nucleotide sequences as well as the amino acid sequences of the HA and NA genes of the 
Palestinian IAV isolates were subjected to bioinformatics analysis using reference sequences 
(see 2.9.6). For this, samples were aligned with reference sequences in MegAlign program. 
Analysis was made for H1, N1, H3 and N2 genes. H1 and N1 were analyzed against H1N1 
isolates form 2009-2015 and the vaccine strain A/California/07/2009(H1N1). Non-synonymous 
as well as synonymous substitutions were identified using MegAlign. All mutations/substitutions 
listed in the following tables were verified using PubMed publications and GenBank archived 
sequences. 
 
 
3.6.1 Nucleotide and Amino Acid Substitution Analysis of the H1 Gene 
Seventeen non-synonymous substitutions were detected in the H1 genes of the Palestinian H1N1 
isolates. Ten of these substitution occurred at least once in the H1N1 reference genes, (Table 
3.5). The literature referring to these substitutions/mutations is also indicated. Five amino acid 
substitutions resulting from six different nucleotide sustitutions were novel.  A 
substitution/mutation is considered novel for the Palestinian isolates, if it did not occur in either 
the H1N1 reference genes, the vaccine strain, and was not referred to in the literature. 
Substitutions Y10H, A13T, and T202S, were found in different Palestinian isolates as well as in 
references. On the other hand, different substitutions were found in each Palestinian isolate.     
Beside the non-synonymous substitutions, 24 synonymous substitutions were detected in H1 of 
the Palestinian H1N1 isolates, 17 of these were also present at least in one H1N1 reference, three 
were present in the vaccine strain, respectively (Table 3.6).  Also here, each Palestinian isolate 
had different simultaneous substitutions. 
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Table 3.5: Non-synonymous substitutions in the H1 gene of Palestinian H1N1 isolates.  The 
AA exchanges and the nucleotide substitution are presented based on the position on the H1 
ORF. This analysis was performed using 23 H1N1 reference genes and the vaccine strain 
(A/California/07/2009(H1N1). Analysis was conducted using MegAlign DNASTAR program.  
Nucleotide 
substitution 
AA 
substitution 
Occurrence 
in samples 
Occurrence 
in references 
Presence in 
vaccine strain 
Citation 
 
C8A A3D 1  No No Novel 
A9C A3D 1  No No Novel 
T28C Y10H 2 1 No - 
C30T Y10H 1  10 No - 
G37A A13T 2 1 No - 
G302A S101N 1  1 No Espinola, 2012 
Emporg et al, 2016 
C538A Q180K 1 11 Yes Yvonne et al, 2015 
Padilla et al, 2014 
C605G T202S 1 8 Yes - 
G605C S202T 3 15 No Li et al., 2012 
Fang et al., 2014 
Mak et al., 2011 Chen et al., 
2012,Padilla et al., 2014 
A668T Y223F 1  No No Novel 
G817A A273T 3 12 No - 
A817G T273A 1 11 Yes Padilla et al, 2014  
A934G I312V 1  1 No Li et al, 2012 
A1429G I477V 1  No No Novel 
A1523G E508G 1  2 No Emporg et al, 2016 
A1537G N513D 1  No No Novel 
C1656A F552L 1  No No Novel 
Bold print: Mutations/substitutions occurring in the vaccine strain. 
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Table 3.6: Synonymous mutations in the H1 gene of Palestinian H1N1 isolates. The 
nucleotide substitutions are presented by the position on H1 gene.  This analysis was performed 
using 23 H1N1 reference genes and the vaccine strain (A/California/07/2009(H1N1). Analysis 
was conducted using MegAlign DNASTAR program. 
Nucleotide 
substitution 
Occurrence 
in samples 
Occurrence in H1N1 
reference subtypes  
Presence in vaccine strain 
 
A150G 1  1 No 
G168A 1  2 No 
A315G 1  No No 
G390A 2  8 No 
C465T 1  11 Yes 
T492C 1  1 No 
C591T 1  No No 
T648C 2  1 No 
A972G 2  5 No 
G1017A 2 9 No 
C1047A 1  No No 
A1173G 2 9 Yes 
T1212C 1  No No 
C1249T 2  8 No 
C1320T 1  No No 
T1327C 2  9 No 
C1362T 1  2 No 
G1395A 1  1 No 
T1467C 1  1 No 
G1473A 1  No No 
G1578A 2  5 No 
T1581C 1 1 No 
T1608C 1  No No 
C1653T 1  10 Yes 
Bold print: Mutations/substitutions occurring in the vaccine strain. 
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3.6.2 Nucleotide and Amino Acid Substitution Analysis of the N1 Gene 
MegAlign analysis revealed 15 different non-synonymous substitutions in the N1 genes of the 
Palestinian H1N1 isolates. Eleven of these substitutions occurred at least in one of the H1N1 
reference genes and two were novel (Table 3.7), while different substitutions were found in each 
Palestinian isolate. The literature referring to these substitutions/mutations is also indicated. A 
substitution/mutation is considered novel, if it did not occur in the H1N1 reference genes and 
was not cited to in the literature. 
Additionally to the non-synonymous substitutions, 21 synonymous substitutions were detected in 
N1 genes of the Palestinian H1N1 isolates, 12 of these were present in at least one H1N1 
reference and four did not occur in any of the H1N1 reference genes, nor were they cited in the 
literature  (Table 3.8).  
While different substitutions occurred simultaneously in each Palestinian isolates, some 
substitutions occurred in 10% of the different Palestinian isolates and were therefore considered 
polymorphic (marked with asterisk).  
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Table 3.7: Non-synonymous mutations in the N1 gene of Palestinian H1N1 isolates. This 
analysis was performed using 20 H1N1 archived reference genes and vaccine strain 
A/California/7/2009 (H1N1) in the MegAlign DNASTAR program.  
Nucleotide 
substitution 
AA 
substitution 
Occurrence 
in samples 
 
Occurrence in 
H1N1 reference 
subtypes  
Presence in 
vaccine strain 
 
Citation 
A11C N4T 1  No No Quiliano et al, 2013 
A83G N28S 1  No No Novel 
G100A V34I 1  4 Yes Arafa et al, 2015 
C118A L40I 4* 6 No Takashita et al, 
2015a 
G199A V67I 3* 4 No Quiliano et al, 2013 
C236T S79L 3* 1 No Quiliano et al, 2013 
T244C S82P 1  3 No Quiliano et al, 2013 
G790A V264I 8* 4 No Komissarov et al, 
2016 
T810A N270K 8* 4 No Komissarov, 2016 
G961A V321I 1  7 Yes  
A961G I321V 10* 11 No Quiliano et al, 2013 
G993T K331N 1  No No Novel 
T1094C I365T 1  No No Guang, 2012 
G1294A E432K 1  4 Yes  
A1294G K432E 9* 14 No Quiliano et al, 2013 
Yamada, 2014 
Bold print: Mutations/substitutions occurring in the vaccine strain.  
(*): Exchanges are considered polymorphisms due to their prevalence in >10 % of the samples.   
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Table 3.8: Synonymous mutations in the N1 gene of Palestinian H1N1 samples.  The 
nucleotide substitution is indicated by the position on the N1 gene.  This analysis was performed 
using 20 H1N1 and archived reference genes and vaccine strain A/California/7/2009 (H1N1) in 
the MegAlign DNASTAR program.  
Nucleotide 
substitution 
Occurrence 
in samples 
Occurrence in H1N1 
reference subtypes 
Presence in vaccine strain 
 
C27A 2* 1 No 
A81G 3* 3 No 
G123A 4* 6 No 
T162C 1  No No 
T225C 1  No No 
C375T 4* 8 No 
A528G 1  2 No 
G615A 1  2 No 
A631T 1  No No 
G660A 1  13 Yes 
T666C 1  No No 
G684A 1  1 No 
T708C 1  No No 
C720A 1  No No 
C729T 1  No No 
C753T 1  No No 
A783G 1  No No 
T846C 9*  4 No 
G1131A 1  5 No 
T1149A 1  12 Yes 
A1158C 1  12 Yes 
Bold print: Mutations/substitutions occurring in the vaccine strain.  
(*): Exchanges are considered polymorphisms due to their prevalence in >10 % of the samples.   
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3.6.3 Nucleotide and Amino Acid Substitution Analysis of the H3 Gene 
Nineteen non-synonymous substitutions were identified in the H3 genes of the Palestinian 
influenza A virus subtype H3N2. Sixteen of these substitutions occurred at least once in the 
H3N2 reference genes, four were novel (Table 3.9).  All Palestinian isolates included at least two 
substitutions. Furthermore, seven of these substitutions were also present in the H3N2 vaccine 
strain, A/Texas/50/2012.  
Twenty-four synonymous substitutions/mutations were detected in the Palestinian H3 genes of 
the H3N2 isolates, 13 occurred also in the H3 genes of the references, seven occurred in the H3 
vaccine strain, 11 did not occur in either reference groups (Table 3.10). Different substitutions 
occurred in each single Palestinian isolate.  
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Table 3.9: Non-synonymous mutations in the H3 gene of Palestinian H3N2 isolates. The 
nucleotide and amino acid (AA) substitutions are presented by the position on H3 gene. This 
analysis was performed in the MegAlign DNASTAR program using 22 archived H3N2 
references, including the H3 gene of the vaccine strain A/Texas/50/2012.  
Nucleotide 
substitution 
AA 
substitution 
Occurrence 
in samples 
Occurrence in 
references  
Occurrence in  
Vaccine strain 
Citation 
A55C I19L  1 12  Yes  
G205A D69N  1 No No Zhong et al, 2013 
G232A E78K  1 1  No Zhong et al, 2013 
C411A N137K  1 No No Novel 
A412G N137K  1 1  No  
A430G T144A  1 5  No Biswas et al, 2016 
A472G R158Q  1 5  No  
G479A S160N  1 11  Yes  
T480G S/N160R  1 No No Novel 
T518C L173S  1 1  No Biswas et al, 2016 
A524T Y175F  1 9  Yes  
C527A T176K  1 12  Yes  
G682A A228T 1 2 No  
G721A D241N 1  9  Yes  
T981A H327Q 1  12  Yes  
G1087A V363K 1  3  No  
T1088A V363K 1  1  No  
A1462G K488E 2* No No Novel 
A1513G N505D 1 11  Yes  
G1633A V545I 4* 1  No  
A1651G I551V 2* No No Novel 
Bold print: Mutations/substitutions occurring in the vaccine strain.  
(*): Exchanges are considered polymorphisms due to their prevalence in >10 % of the samples.   
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Table 3.10: Synonymous mutations in the H3 gene of Palestinian H3N2 isolates. The 
nucleotide substitutions are presented by the position on the H3 gene. This analysis was 
performed in the MegAlign DNASTAR program using 22 archived H3N2 reference genes, 
including the H3 gene of vaccine strain A/Texas/50/2012.   
Nucleotide 
substitution 
Occurrence 
in samples 
Occurrence in H3N2 
reference subtypes 
Occurrence in vaccine H3N2 
strain 
T18C 1  1 No 
C90T 1  No No 
A138G 1  12 Yes 
C144T 1  No No 
G171A 1  1  Yes 
T213C 7* 1 No 
A231G 1  No No 
C244T 1  No No 
G273A 1  No No 
C396T 1  No No 
T480G 1  No No 
T480C 1  No No 
C600T 7* 1 No 
A693G 1  11  Yes 
T870A 7* 1  Yes 
G978A 1  No No 
A1260G 1  12  0 
T1296A 1  5  No 
T1368A 4* No No 
A1437C 1  12  Yes 
A1491C 1  11  Yes 
G1518A 1  10  Yes 
A1533T 1  1  No 
G1683A 1  No No 
Bold print: Mutations/substitutions occurring in the vaccine strain.  
(*): Exchanges are considered polymorphisms due to their prevalence in >10 % of the samples.   
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3.6.4 Nucleotide and Amino Acid Substitution Analysis of the N2 Gene 
Nine non-synonymous substitutions were detected in the N2 genes of the Palestinian influenza A 
virus isolates, subtype H3N2. Three of these substitutions were not present in the archived 
reference strains or the vaccine strain, and were therefor considered novel (Table 3.11).   
18 synonymous substitutions/mutations were detected in the Palestinian N2 genes of the H3N2 
isolates, ten occurred also in the N2 genes of the references, while only one was present in the 
vaccine strain, and eight were novel substitutions (Table 3.12). Different synonymous and non-
synonymous substitutions occurred in each single Palestinian isolate.  
 
Table 3.11: Non-synonymous substitutions in the N2 gene of Palestinian H3N2 isolates.  The 
nucleotide substitution is presented by the position on N2 geneThis analysis was performed in 
the MegAlign DNASTAR program using 20 H3N2 archived reference N2 genes, including the 
N2 gene of the vaccine strain A/Texas/50/2012. 
Nucleotide 
substitution 
AA 
substitution 
Occurrence 
in samples 
Occurrence in 
H3N2 references  
Occurrence in  
Vaccine strain 
Citation 
A374G D125G 1  No No Novel 
G661A D221K 1  2 No - 
T663C D221N 1  No No Novel  
A800C K267T 1  11 Yes - 
C800A T267K 6 7 No Belanov et al, 2015 
C987A N329K 1  No No Novel 
G1138A V380I 1  12 Yes - 
A1138G I380V 5 7 No Belanov et al, 2015 
T1175C I392T 1  4 No Belanov et al, 2015 
Bold print: Mutations/substitutions occurring in the vaccine strain.  
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Table 3.12: Synonymous mutations in the N2 gene of Palestinian H3N2 isolates. The 
nucleotide substitution is presented by the position on N2 gene. This analysis was conducted 
using the MegAlign DNASTAR program and N2 gene of 20 H3N2 archived reference, including 
the vaccine strain A/Texas/50/2012.  
Nucleotide 
substitution 
Occurrence 
in samples 
Occurrence in H3N2 
reference subtypes 
Occurrence in vaccine H3N2 
strain 
C84T 1  4  No 
C129T 1  No No 
G204A 2 3 No 
C339T 1  No No 
G408A 1  2 No 
G429A 1  1 No 
A447G 3 1 No 
G585A 1  No No 
T663C 1  No No 
G678A 1  No No 
C825T 1  2 No 
A888G 1  4 No 
A981G 1  No No 
T1065C 1  1 No 
G1089A 1  12 Yes 
C1155T 1  2 No 
G1170A 1  No No 
A1239G 1 No No 
Bold print: Mutations/substitutions occurring in the vaccine strain.  
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3.7 Phylogenetic Analysis of the Palestinian H1N1 Isolates 
To verify the different influenza A subtypes found among Palestinians, international and regional 
archived subtypes were downloaded into the MegAlign program and subjected to phylogenetic 
analysis using the program’s default setting.  Overall, the percent identity between Palestinian 
isolates was above 98%, and that between Palestinian and reference H1N1 and H3N2 were 
above 93%.   
Figures 3.11 and 3.12 show the phylogenetic analysis of the Palestinian H1N1 isolates, the H1 
(Figure 3.11) and the N1 (Figure 3.12) sequences separately.  The H1 and N1 sequences of the 
Palestinian isolate number 21 clustered on a sub-branch with a US American isolates from 
California (A/California/80/2015(H1N1).  The H1 sequence of the Palestinian H1N1 isolate 46 
clustered on an independent branch from reference genes (Figure 3.11), while its N1 sequence 
was closely related to most of the other Palestinian N1 sequences (Figure 3.12).  The H1 
sequence of sample 167 clustered on a sub-branch with a reference isolate from Indore, India 
(Figure 3.11), its N1 sequence however, was closely related to other Palestinian N1 sequences. 
Palestinian isolates 166, 165, 145, 141 were closely related to each other and clustered on one 
branch (Figure 3.12).  Palestinian isolates 172 and 170 clustered on two sub-branches, however 
170 was closely related to A/Florida/92/2015(H1N1).  Sample 188 clustered away from the other 
Palestinian and reference N1 genes on its own branch.  Finally, Samples 301, which was isolated 
during the 2013 outbreak, was the Palestinian isolate most close to the vaccine strain 
A/California/07/2009(H1N1) (Figures 3.11 and 3.12). 
Figures 3.13 and 3.14 show the phylogenetic analysis of the Palestinian H3N2 isolates.  The 
Palestinian H3 sequences of isolates 93, 89, 74, 61, 60 and 38 clustered together on one branch 
on the top of the tree, while 109 and 177 clustered together on the bottom of the tree, isolates 9, 
4, and 1 clustered together between reference genes.  The H3 sequence of Palestinian isolate 29 
was the only one related to regional isolate from Riyadh, however its N2 sequence clustered far 
away from the Riyadh strain (Figures 3.13 and 3.14).  The N2 sequence of Palestinian isolate 1 
was identical with an archived a Hong Kong strain (Figure 3.14).  N2 sequences of Palestinian 
isolates 74 and 61, 60 and 38 were identical; all four were closely related to a Helsinki strain.  
Finally, the N2 of the Palestinian isolate 9 clustered with reference N2 genes from Bangkok, 
Thailand and Siberian Novosibirsk, Russia respectively (Figure 3.14).   
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Figure 3.11: Phylogenetic tree of the H1 gene of Palestinian isolates.  The phylogenetic tree 
was generated using the BIONJ algorithm (MegAlign Pro-DNASTAR program).  The length of 
each pair of branches represents the distance between sequences pairs, the vaccine strain is in 
green print and the Palestinian isolates are in red print. 
21-H1 
301-H1 
A/California/07/2009(H1N1) 
46-H1 
167-H1 
75 
 
  
Figure 3.12: Phylogenetic tree of the N1 gene of Palestinian isolates.  The phylogenetic tree 
was generated using the BIONJ algorithm (MegAlign Pro-DNASTAR program).  The length of 
each pair of branches represents the distance between sequences pairs, the vaccine strain is in 
green print and the Palestinian isolates are in red print. 
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165-N1 P 
145-N1 P 
141-N1 P 
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A/Texas/50/2012(H3N2) 
93-H3 
89-H3 P 
74-H3 
61-H3 
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9-H3 
4-H3 
1-H3 
109-H3 
177-H3 P 
29-H3 
A/Washington/34/2015(H3N2) 
 
Figure 3.13: Phylogenetic tree of the H3 gene of Palestinian isolates.  The phylogenetic tree 
was generated using the BIONJ algorithm (MegAlign Pro-DNASTAR program).  The length of 
each pair of branches represents the distance between sequences pairs. The Palestinian isolates 
are in red print; the vaccine strains of 2014-2015 and 2015-2016 are in green print.  
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A/Texas/50/2012(H3N2) 
A/Washington/34/2015(H3N2) 
9-N2 P 
1-N2  
29-N2 
74-N2 
61-N2 
60-N2 
38-N2 
 
Figure 3.14: Phylogenetic tree of the N2 gene of Palestinian isolates.  The phylogenetic tree 
was generated using the BIONJ algorithm (MegAlign Pro-DNASTAR program).  The length of 
each pair of branches represents the distance between sequences pairs. The Palestinian isolates 
are in red print; the vaccine strains of 2014-2015 and 2015-2016 are in green print.  
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4. Discussion 
Human influenza A viruses continues to show significant deleterious impact on public health and 
the global economy by causing annual outbreaks and occasional pandemics. The swine influenza 
pandemic in 2009, refreshed the memories of the Spanish flu pandemic back in 1918-1919, and 
prompted the experts to develop a new vaccine within a very short period of time.  Despite the 
highly standards of molecular techniques and superior medical advances, an outbreak of a 
respiratory tract virus has the world on tenterhooks and calls for continuous updates and research 
in the field.   
Molecular biology techniques of today enable detailed insight into the viral genetics and deliver 
reliable information on genotypes and drug resistance. Influenza A virus is subtyped based on 
the antigenicity of its two surface glycoproteins, hemagglutinin and neuraminidase. H1N1 and 
H3N2 are currently the major circulating subtypes and have been infecting the human population 
for several decades (WHO, FluNet 2016). Indeed, Lin et al. (2013) revealed that H1N1 and 
H3N2 subtypes have been circulating together since 1977. 
Influenza virus rapid evolution by both antigenic shift and antigenic drift is a significant 
challenge for vaccine design, therefore constant monitoring of genetic and antigenic properties is 
required for detection of newly emerging strains and annual revision of influenza vaccine 
composition.  In recent years, gene sequences have become available for a large number of viral 
strains creating a diverse pool of influenza A viruses from historical and current isolates 
collected in multiple geographic regions. 
Genotyping and identifying Influenza A in the different geographic areas could reveal 
mechanisms of virus evolution and spread, and predict mutations causing drug resistance and 
increased virulence.  Worldwide, Influenza A typing and surveillance reports are increasing since 
the H1N1 pandemic outbreak in 2009.  Although limited, scientific reports from the Arab world 
and the region increased since 2009, yet there had been no one single report on influenza A types 
circulating among Palestinians, which was the aim of this study. 
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4.1   Sample Size and Collection Time 
The sample size intended for collection for this work was 300.  Influenza accounts for 5-15% of 
upper respiratory tract infections (WHO, FluNet, 2016), so the aim was to collect around 30 
positive influenza A samples and characterize the HA and NA genes.  The process of collection 
and testing was continuous, i.e. samples collected were subjected to IAV molecular biology 
testing before the desired sample size was reached.  The sample size of 300 was collected by 
October 2015, however we were unable to test the remaining 100 samples. Nevertheless 25% of 
the first 200 samples, collected within four-months period between February and January 2015 
tested positive for IAV.  The high percentage of IAV positive samples could be attributed to the 
targeted study sample; kindergarten children and hospitalized adults with influenza-like 
symptoms.  Both age groups are more likely to suffer from complications due to influenza A 
infection (Fiore et al., 2008).   Another reason for this high percentage of influenza A infection is 
the collection time.  Although unpredictable and variable, influenza activity starts usually around 
October, peaks between December and March, and ends in May (CDC, Flu Website, 2016).  
According to the WHO reports for 2015, influenza A spread throughout the Middle East between 
January and May, and peaked in February (WHO, FluNet, 2015), which coincided with the 
collection time of samples in this work.  
 
 
4.2  Influenza A Subtypes Circulating in Palestine 
In line with the WHO reports (WHO, FluNet, 2015), both H1N1 and H3N2 were circulating in 
Palestine in the flu season 2015; 48% of the positive IAV samples were H1N1, 52% were H3N2, 
respectively.  Interestingly, also the distribution of the circulating influenza A types coincided to 
some extent with the WHO records for the Middle East (WHO, FluNet, 2015).  According the to 
WHO records (WHO, FluNet, 2015), the season started in January, peaked in February, and 
started decreasing in March with an overall predominance of H3N2.  Our data indicated that 
H3N2 was circulating predominantly between February and March among Palestinians, which is 
in agreement with the WHO data. WHO reported an increase of the A(H1N1)pdm09 towards the 
end of March and was predominant in April (WHO, FluNet, 2015), which is also in agreement 
with the data presented in this work.  
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A chi-square test of independence based on the exact permutation distribution of the chi-square 
statistic was performed to test whether being infected by H1N1, H3N2, or not is related to the 
month of sampling. The test was significant for both subtypes: H1N1 (chi-squared = 25.663, p-
value = 0.0001), H3N2 (chi-squared = 11.954, p-value = 0.008501). 
 
 
4.3   The Relationship between Influenza A Infection and other Variables  
4.3.1   Age and Sex 
The rate of IAV infection among the different age groups was almost equal among age groups  > 
1-6 years, 7-18 years, and > 18 years.  The infection rate was highest (30%) in the infants (group 
≤ 1 year).  A statement  couldn’t  be made regarding the risk group >64 years, as there was only 
five participants >64 years in the study, and only one of them tested positive for IAV.  The 
subtype causing infection was rather variable in the different age groups.  Subtype H3N2 was 
responsible for most IAV infections in the youngest age groups  (≤ 1 year and > 1-6 years), while 
H1N1 caused most IAV infections in the adults group (> 18 years).  These findings are in 
agreement with other studies (Yang et al., 2015, Mosnier et al., 2015).  Nevertheless, chi-square 
test of independence performed on our data revealed that neither H1N1 nor H3N2 infection was 
related to age (p-value=0.17 for H1N1 and 0.25 for H3N2 respectively).  
Our results indicated that more males suffered from IAV infection with male to female ratio of 
1.2 and that H3N2 was more common among males, while H1N1 was more common among 
females. Chi-square test of independence revealed that these three finding are not significant (p-
value=0.5, 0.08 and 0.5). Studies on gender associated infection increased since the 2009 
pandemic with different findings in different countries (reviewed in WHO report 2010).  More 
conclusive are studies relating severity of infection, morbidity, and mortality to gender (Klein et 
al., 2010, Viboud et al., 2013, Jacobs et al., 2012). 
 
 
4.3.2  Residency and Collection Site 
According to the data presented here, there was also lack of significance between IAV infection, 
infection with subtype H1N1 or H3N2, and residency (p-value=1.0, 0.8, and 1.0 respectively).  
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As a matter of fact, regional residency affects the circulating subtypes in different parts of the 
world, i.e. H3N2 was the predominantly circulating subtype in the US for the season 2014-2015, 
the same season we collected our samples (Appiah et al., 2015).  According to the WHO reports 
for influenza activity and circulating subtypes, H3N2 was also the major subtype circulating in 
Europe and temperate eastern Asia, with minor activity of A(H1N1)pdm09, while 
A9H1N1)pdm09 was predominant in tropical Asian countries such as Bhutan and India (WHO 
FluNet, 2015).  In North Africa and the middle East, H3N2 and A(H1N1)pdm09 were co-
circulating in Egypt, while A(H1N1)pdm09 was predominant in Algeria and Iran, respectively 
(WHO FluNet, 2015).   
There was also no significant difference between the collection site and IAV infection, H1N1 
infection, and H3N2 infection (p-values 0.8, 0.4, and 0.8).  It is implicative that the virulence of 
IAV ranges from mild respiratory infection that needs no medical attention such as cases coming 
from kindergartens and private practices to moderate infection that result in visiting outpatient 
clinics up to severe clinical manifestations, which require hospitalization.  It is widely accepted 
that the vast majority of Influenza A patients undergo an uncomplicated course of illness, which 
can be managed in an outpatient setting without the need of hospitalization (Fiore et al., 2008, 
Naoufal et al., 2012, WHO FluNet, 2016).  Complications and mortality rates are generally high 
in the age group older than 65 years (Fiore et al., 2008), which was not present in our study 
sample.  
Looking further into the distribution of subtypes, connecting residency and site of collection, it is 
clear that IAV infection with subtype H3N2 was highest in those participants residing Jerusalem.  
This result is due to the fact that the majority of participants residing Jerusalem were 
kindergarten children, an age group, which is more likely to be infected with H3N2 according to 
our findings and that of other researchers (Yang et al., 2015, Mosnier et al., 2015). 
 
 
4.3.3  Traveling Outside Palestine and Living Near Poultry Raisers 
Significant relationship was lacking between IAV infection, H1N1 infection, H3N2 infection and 
traveling outside Palestine (p-value 1.0, 0.6, and 0.3), and residency near poultry farms (p-
value=0.8, 0.5, and 1.0).   
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Frequent traveling is a known risk factor for acquiring pathogenic infections, especially 
respiratory tract pathogens including influenza (Mutsch et al., 2005, Leder et al., 2003).  We 
propose that a larger number of samples could be more conclusive to deliver a statement in this 
regard.  In regard to the lack of significance for residing near poultry, we propose that study 
participants, who checked yes for living near poultry, may have meant small private poultry of 
few animals, which is very common in Palestine.  Live poultry markets had been the major 
source of infection with high pathogenic avian influenza  (Wan et al., 2011), but markets in that 
mass do not exist in Palestine.    
 
 
4.3.4  Influenza-like Symptoms, Vaccination, and Drug Administration 
The relationship between IAV infections, infection with subtype H1N1, infection with subtype 
H3N2 and influenza-like symptoms was not significant (p-values= 0.86, 1.0, and 0.7).  Likewise 
insignificant was the relationship between IAV infections, infection with subtype H1N1, 
infection with subtype H3N2 and vaccination, and drug administration (p-values=0.49, 1.0, and 
0.6), and  (p-values 1.0, 1.0, 1.0), respectively. 
Generally, vaccination prevents infection with Influenza A and leads to mild symptoms in case 
of infection.  Also here we propose that the number of participants of vaccinated versus not 
vaccinated was too small to make conclusions.  However, it was interesting that H1N1 and 
H3N2 infection distributed almost equally in vaccinated and not-vaccinated IAV positive groups, 
which coincides with the fact that both subtypes were circulating in Palestine and subsequently 
caused almost equal infections.  
In regard to the influenza-like symptoms, runny nose (rhinorrhea), cough and fever seemed to be 
important clinical symptoms of IAV infection in both subtypes. Runny nose was the major 
clinical symptom observed in this study with 84.7% in IAV infected cases.  It is noteworthy to 
mention that when samples were collected from Kindergartens, the teachers were asked about 
children with respiratory tract infection and they pointed out mainly those children with runny 
nose, which might cause an increase in the rate of runny nose against other symptoms.  In 
another regional setting, Naoufal et al. (2012) revealed that cough and fever were the major 
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symptoms of IAV infection with rates of 87% and 73%, respectively, whereas rhinorrhea 
accounted for only 33%.  Similar rates were also reported from Oman (Ahmad et al., 2011). 
The type of drug administrated was mainly antibiotics and therefore did not affect influenza 
infection, however, one confirmed IAV infection was a hospitalized patient. NPA was collected 
from that patient after receiving Tamiflu and therefore IAV could not be detected in that sample.  
Generally, administration of antibiotics and Tamiflu remains to be a major obstacle for 
successful management of respiratory tract infections in Palestine, as decisions are not made 
based on laboratory diagnostic due to the lack of fast, reliable, and efficient molecular biology 
testing of viruses causing respiratory tract infections. 
 
 
4.4   Efficiency of the RT-PCR Testing 
With the exception of the primer pair designated for the amplification of an M gene region, all 
other primers were selected based on WHO recommendation for the detection of circulating 
H1N1 and H3N2 subtypes (see Table 2.1).  Screening for the presence of IAV was initially 
performed using a primer pair specific for the M gene of IAV, which amplified the expected 
PCR product in 50% of the samples collected at the beginning of this research. 20 samples tested 
positive for the M gene were subjected to H1N1 and H3N2 RT-PCR simultaneously. Hereby, 
primer pair N1F2/N1R2 was used to identify H1N1 subtype, and primer pair H3F1/H3R1 to 
identify H3N2. Interestingly, only five of these twenty samples tested positive for either H1N1 or 
H3N2. Therefore, screening step with the M primer pair was skipped for specifity reasons.  All 
samples were screened for H1N1 and H3N2 simultaneously using specific primer pairs.  
The first positive H1N1 and H3N2 isolates were subjected to screening with the entire set of 
primers for each subtype (see Table 2.1). In some cases the RT-PCR reactions using the 
H1F1/H1R1 primer pair resulted in a second lower band around 1000 bp, while the size of the 
expected band was 1264 bp.  Sequence analysis revealed that the 1000 bp band was non-specific 
to Influenza A, therefore the PCR products were clearly separated and distinguished by longer 
running of the gel electrophoresis as demonstrated in Figure 3.10A. In regard to efficiency, 
primer pair N1F2/N1R2 produced the strongest PCR fragment for different samples and 
therefore was used to screen for H1N1 subtype.  
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H3F2/H3R2 primer pair showed the highest efficiency and was therefore used to screen for 
H3N2 subtype (Table 2.1). Efficiency of primer pair N2F1/N2R1 and N2F2/N2R2 was relatively 
low in some samples. In order to overcome this obstacle, the sequences of those H3N2 samples 
retrieved with these primer pairs were analyzed. This analysis showed that these samples were 
presented with nucleotide substitutions, which can cause this low efficiency. Based on this 
analysis new primers were designed to replace N2R1; N2R1m, and another one to replace N2F2; 
N2F2m, respectively (Table 2.1).  
The efficiency of the different primer pair was not equally good, which remarkably affected the 
RT-PCR yield in samples with low viral load.  A poor RT-PCR yield reflected a low viral load, 
in such cases; RT-PCR harvest was too weak to deliver a successful sequence.   
 
 
4.5   Substitution Analysis of the Palestinian Isolates’ HA and NA Genes 
Amino acid substitutions in HA may affect the receptor-binding site and can influence the 
cellular host range and tissue tropism that may alter virulence.  Specific amino acid residues in 
HA determine the receptor binding specificity of human and avian influenza viruses and these 
specific residues differ among virus subtypes. Amino acid substitutions in the NA gene may 
affect release of virus progeny and cause drug resistance. 
 
 
4.5.1   Substitution Analysis of the Palestinian H1N1 Isolates 
A total of 17 non-synonymous substitutions were detected in the H1 genes of the Palestinian 
H1N1 isolates. Substitution S101N found in one isolate has been proposed to play a role in 
adaptation to the human host and was being detected in other studies at high frequencies 
(Espinola, 2012).  Substitution S202T was found in three Palestinian isolates including the one 
from 2013.  This substitution is located in the antigenic site Sb, reported in five different studies 
(Fang et al., 2014; Li et al., 2012; Padilla et al., 2014; Mak et al., 2011, Chen et al., 2012) and 
was found frequently in H1N1 strains causing severe infections (Chen et al., 2012).  
Substitutions T202S and Q180K, occurred in one Palestinian isolate were located at an antigenic 
site, which is under significant positive selection pressure in H1N1 strains (Su et al., 2015). Su et 
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al. (2015) detailed that positive selection in the early 2009 H1N1 pandemic period appears to 
have been predominantly driven by adaptation to the new human host, while in the later post-
pandemic period positive selection was directed towards the viruses escaping the host immune 
response. A/California/07/2009-like virus continues to be included in the vaccine 
recommendation ever since the pandemic in 2009, host immune driven substantial antigenic 
change in that strain started occurring two years after its appearance and may result in further 
changes later, which would demand changing the vaccine recommendation.  A273T substitution 
(occurred in three Palestinian isolates) was detected along with the Q180K substitution in 
isolates from Peru during the A(H1N1)pdm09 outbreak in 2013 (Padilla et al., 2014).  
Substitution I312V and E508G were described in two different studies without being attributed 
to any biological function (Li et al., 2012, Emborg et al., 2016).  Substitutions A3D, Y223, 
N513D, and F552L were novel as they were not reported in the literature yet, nor did they occur 
in NCBI-archived sequences. Substitution attributed to fatal influenza A infection such as 
D239G in the H1 gene (Espinola, 2012, Su et al., 2015) did not occur in any of the Palestinian 
isolates. 
Fifteen different non-synonymous substitutions were detected in the N1 genes of the Palestinian 
H1N1 isolates, two of which were novel.  Other non-synonymous substitutions were reported in 
different studies without being attributed to biological function, such as K432E, reported by 
Yamada et al. (2014), V34I, reported by Arafa et al., (2015), L40I, and S82P, reported by 
Takashita et al. (2015a).  All these mutations occurred at least in one Palestinian isolate. V264I 
and N270K substitutions, each present in eight Palestinian isolates and E432K, present in one 
sample were located with a region identified as NA antigenic site (Maurer-Stroh et al., 2009). 
V264I and N270K were also reported by Komissarov et al. (2016), who proposed that 264 is a 
position involved in viral host adaptation (Reid et al., 2000). Substitutions L40I, V67I, S79L, 
V264I, N270K, I321V, and K432 are considered polymorphic due to their presence in more than 
10% of the Palestinian isolates. 
Interestingly, all substitutions occurring in the vaccine strain A/California/07/2009, also occurred 
in the Palestinian sample 301.  301 was isolated during the 2013 outbreak and was initially used 
as a positive control.   This observation is crucial and emphasizes the fact that immune driven 
substitution occurs in the virus after being circulating for a while (Su et al., 2015).  The fact that 
86 
 
301 was isolated in 2013, it was the Palestinian isolate most close to the vaccine strain. Finally, 
none of the Substitutions found in the N1 genes were attributed to drug resistance.  
 
 
4.5.2 Substitution Analysis of the Palestinian H3N2 Isolates 
Ninteen non-synonymous substitutions were detected in the H3 genes of the Palestinian 
influenza A virus subtype H3N2.  Substitution A228T was present in one Palestinian sample. 
Position 228 is critical for the receptor binding specificity of H3 strains (Matrosovich et al., 
2000). T228A was reported in different studies (Zhong et al., 2013) and different isolates and 
occurred in 10 Palestinian isolates as well as in the vaccine strain.  Substitutions T144A and 
L173S occurred in one Palestinian isolate, both positions localize to the antigenic site of the HA 
domain and were proposed to play a role affecting the antigenicity/virulence of the H3N2 viruses 
(Biswas et al., 2016).  Substitutions E78K and D69N occurred in one Palestinian isolate, both 
positions were described earlier as mutation sites in the HA gene of influenza H3N2 strains 
isolated between 2011 and 2012 from Guangdong (Zhong et al., 2013). Two non-synonymous 
mutations occurred at position 160 in one isolate each, S160N and S160R. Substitutions at 
position 160 of HA may lower the affinity of F045-92-like and 2D1-like host antibodies, which 
target HA head region of the virus (Belanov et al., 2015). 
Nine different non-synonymous substitutions were detected in N2 genes of Palestinian influenza 
A H3N2 isolates.  Four of these substitutions (D125G, K267T, V380I, I329T) occurred in one 
single Palestinian isolate (isolate 29), which was collected from a two-year old toddler at a 
private clinic in Ramallah. One of these substitutions, D125G, was novel, two of these 
substitutions, K267K and V380I, occurred in other NCBI-archived reference sequences, while 
substitution I329T was reported by Belanov et al. (2015) without being attributed to a biological 
activity.  Palestinian substitutions T267K and I380V, were also reported by Belanov et al. (2015) 
without being attributed to a biological activity.  None of the substitutions detected in the N3 of 
the Palestinian isolates caused drug resistance. 
The ratio of non-synonymous (dN) to synonymous non-polymorphic substitutions (dS) is an 
indicator for the evolutionary relevance of a set of mutations.  There are quite different 
complicated methods to calculate this ratio (ω = dN/dS) (Chen and Sun, 2011). Kryazhimskiy 
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and Plotkin (2008) suggested that a strong positive selection is expected to produce dN/dS<1 
among population samples, which applies for all four genes tested in this work.   
 
4.6 Phylogenetic Analysis and Sequence Distances 
A(H1N1)pdm09 is the predominant H1N1 subtype circulating among humans ever since the 
2009 pandemic.  The Palestinian H1N1 isolates were identified as A(H1N1)pdm09 strains and 
their sequence percent identity with the A(H1N1)pdm09 vaccine strain A/California/07/2009 
ranged from 97.6 to 99% with the percent identity higher in the N1 genes.  Sequence percent 
identity among Palestinian H1N1 isolates ranged from 98.6 to100%. 
Sequence percent identity between vaccine strain for the season 2014-2015 
A/Texas/50/200/2012(H3N2) and the Palestinian H3N2 isolates ranged between 98.2-99.4 with 
percent identity higher in the N2 genes.  Sequence percent identity between vaccine strain for the 
season 2015-2016, lineage A/Switzerland/9715293/2013(H3N2), presented by the 
A/Washington/34/2015(H3N2), and the Palestinian H3N2 isolates ranged between 97.9-99.3 
with percent identity higher in the N2 genes.  Sequence percent identity among Palestinian H3N2 
isolates was ranged from 98 to 100%. 
Sequence percent identity between Palestinian Isolates and regional ones was lower than that 
with archived sequences from other parts of the world, which is clearly illuminated in the 
phylogenetic trees (Figures 3.10-3.11). Palestinian H1 genes clustered closely to archived 
sequences from the USA, including the vaccine strain, while one single Palestinian isolate 
clustered closely to an isolate from Indore, India.  Similarly, most Palestinian N1 genes clustered 
closely with different Isolates from the USA.  Isolate 301 was the Palestinian isolate most close 
to the vaccine strain and clustered with isolates from Kenya, Oman, Jeddah, Amman, and Israel, 
all isolated during the 2009 pandemic or the 2013 A(H1N1)pdm09 outbreak. 
Palestinian H3 genes clustered rather together and yet close to strains from the USA, South 
Korea, Japan, and Israel.  Interestingly, N2 genes clustered closely with an isolate from Helsinki, 
Finland, while sample one isolate (sample number 1) was identical with an archived sequence 
from Hong Kong.  Sample number 1 was collected from a hospitalized toddler. 
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Taken together the Palestinian circulating H1N1 and H3N2 strains in the season 2014-2015 
comply with the strains included in the vaccine, and therefore the vaccine efficacy should have 
been high among Palestinian vaccinees in that season. 
 
 
4.7 Conclusions and Recommendations 
Worldwide, genome analysis of human Influenza viruses is an essential approach in 
identification of circulating strains of H1N1 and H3N2 subtypes and plays a critical role in 
making the most appropriate decision, which strains should be included in the annually prepared 
vaccine cocktail.  
Using the NCBI search machinery looking for regional archived sequences from the Middle East 
region was not very productive; obviously more efforts need to be done to improve regional 
contribution.  Although most outbreaks originated from Far East countries, the 1918/1919 and 
2009 pandemics did not. The research presented here is the first HA and NA genetic analysis of 
the influenza A circulating in Palestine and provides the scientific community with the first 
insight into genetic properties of the virus including information regarding vaccine efficacy.  
Studies as the one presented here should be performed annually to validate the vaccine efficacy, 
as is the case in most developed countries.  This current study showed that the vaccine efficacy 
in Palestine for the influenza season 2014/2015 was high, based on the fact that the circulating 
strains aligned with the strains included in the vaccine. This however, may not be the situation 
every season.  
Some of the substitutions identified in this study were novel Palestinian substitutions; future 
local and regional studies would be essential to verify the significance of these substitutions. 
Nevertheless, the phylogenetic trees showed that Palestinian isolates did not necessary cluster 
within regional isolates, an indication, that traveling contributes to global spread of viruses. This 
is also the reason, why the vaccines recommendations for the northern and southern hemispheres 
in the last years were the very same. Distances between countries become meaningless with the 
outbreaks, and dormant viruses, as SARS, Ebola, Zika, and influenza A, can catch the world by 
surprise. Worldwide, screening and typing of circulating viruses became an essential tool in 
prevention and future health planning, and should be applied widely in the region.  
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  امسح ودراسة النماط الجزيئية لفيروس الانفلونز A بين الفلسطينيين 
 
  ياسين البكري قاداعداد: ميسون ص
 إشراف: الدكتورة ميساء العزة
 
 الملخص:
 
  ا يتسبب فيروس الانفلونز A )VAI( بنسبة اصابات ووفيات مرتفعة اضافة الى العبأ الاقتصادي في جميع انحاء العالم.  VAI 
  ة و سلسلة احادية سلبية ومجزأة من المادة الوراثيذ فيروسوه ANR المنتمية لعائلة  eadirivoxymohtrO نواع .  يتم تحديد ا
 VAI بالاعتماد على اثنان من بروتينات السطح الخارجي للفيروس   )AH( ninitulggameh و  )AN( esadinimaruen.  
  1N1H و   2N3H هما نوعان من فيروس   VAI الجينية لسلالات الاكثر انتشارا بين البشر. ان استمرارية تحديد الانماط   VAI
  سلالات خلال الموسم يساهم بشكل فعال بالتعرف على الانواع السارية وبالتالي اختيار 1N1H و   2N3H التي ستدخل في  
  نواع لونزا. ان دراسة االتصنيع السنوي للقاح الانف VAI تناقص مستمر مقارنة  لها فيلجيني السارية في منطقتنا وتحديد التسلسل ا 
  باء ظهور و هذا النوع من الفيروسات بعدالدراسات في المناطق الاخرى بالرغم من الاهتمام والجهود التي تركزت على مع 
 1N1H  ه اول دراسة شاملة لسلالات فيروس  هذ. تعد 9002عام  VAI عينة  افرازات 002السارية في فلسطين حيث تم جمع  
 المجاري التنفسية  etaripsa laegnyrahposaN شباط والخامس من ايار من اشخاص يعانون من اعراض ما بين العاشر من 
 امراض تنفسيةما بين بسيطة  الى شديدة وتم فحص وجود فيروس  VAI باستخدام تقنية   RCP-TR على الجينين   AH و  AN
  لنوع ل تنتمي %84 ، ات وجود الفيروسمن العين %52وقد اظهرت  1N1H  لنوعل تنتمي %25و  2N3H . الاصابة بالنوع
  1N1N  عاما بينما كانت الاصابة بالنوع 81كانت اكثر انتشارا في شهر نيسان وعند الاشخاص الكبار فوق  2N3H  
  ات اعوام. تم بنجاح الحصول على التسلسل الجيني لجين 6ر و لدى الاطفال تحت ذااكثر انتشارا في  ا AH و  AN 32في   عينة،
  السلالات المرجعية  وكانت نسبة تطابق التسلسل الجيني بين سلالات الفيروس في العينات الفلسطينية اعلى من نسبتها مع 
  ة (المؤرشفة في بنك الجينات. تم الكشف عن استبدالات جينية غير مرادف noitutitsbus suomynonys noN) عددها
  بالجينات  6و   22، 51، 41 1H,1N ,3H ,2N  ه الاستبدالات الجينية هذعض تباعا، يتضمنها استبدالات جينية غير مألوفة. ب
 في مواقع مستضدية )setis cinegitnA) مثل الاستبدالات S202T و  K081Q في الجين   1H لك الاستبدالات  ذوك  A441T
 901
 
  و  S371L في الجين  3H  بعض   ه الاستبدالات الجينية في استجابة جهاز المناعة لدى الجسم المضيف.هذ، وقد تؤثر 
  لات (تمركزت في مواقع الربط مع المستقبى الاستبدالات الاخر setis gnidnib rotpeceR) مثل الاستبدالة الجينيةA822T 
 في الجين  3H ه الاستبدالات بتغيير مجال انواع المضيف القابل للاصابة بفيروسهذ، وقد تؤثر  VAI وبالتالي تغيير حدة 
  تسبب بنتائج قاتلة.ر على اي من الاستبدالات الجينية المعروفة بمقاومة دواء الانفلونزا ولا بتلك التي تالفيروس. لم يتم العثو
 اظهرت تحليلات النشوء والتطور الوراثي ان سلالات 1N1H و 2N3H في فلسطين ليست قريبة من تلك السارية في منطقتنا 
  قي الضوء ه الدراسة مهمة لكونها الاولى التي تلهذى الاكثر بعدا عنا.  وانما تتكتل اكثر مع السلالات في مناطق العالم الاخر
 على الخصائص الجينية  للجينات AH و  AN لفيروسات   VAI السارية في فلسطين. 
 
 
 
 
 
 
 
